NUTRIENT SENSING
December 8, 2023ฮ-GLUCOSIDASE INHIBITORS
December 8, 2023
- Comparative review of dipeptidyl peptidaseโ4 inhibitors and sulphonylureas
- Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences
- Dipeptidyl peptidaseโ4 (DPPโ4) inhibitors for type 2 diabetes mellitus
- Safety of dipeptidyl peptidase 4 inhibitors: a perspective review
- Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors
- Dipeptidyl peptidaseโ4 inhibitors in the treatment of type 2 diabetes: a comparative review
- Whey proteins as source of dipeptidyl dipeptidase IV (dipeptidyl peptidase-4) inhibitors
- Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4)
- Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions
- Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors
- The nonglycemic actions of dipeptidyl peptidase-4 inhibitors
- Dipeptidyl peptidase-4 (DPP-4) inhibitors in the management of diabetes
- Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials
- Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus
- A review of dipeptidyl peptidaseโ4 inhibitors. Hot topics from randomized controlled trials
- Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials
- Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes
- Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions
- Tolerability of dipeptidyl peptidase-4 inhibitors: a review
- Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis
- Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes
- Dipeptidyl peptidase-4 inhibitors: 3 years of experience
- Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis
- Dipeptidyl peptidaseโ4 inhibitors for the treatment of type 2 diabetes mellitus
- Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials
- Predictors of response to dipeptidyl peptidaseโ4 inhibitors: evidence from randomized clinical trials
- Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes
- Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety
- Dipeptidyl peptidaseโ4 inhibitors and cardiovascular risk: a metaโanalysis of randomized clinical trials
- Overview of the gliptin class (dipeptidyl peptidase-4 inhibitors) in clinical practice
- Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors
- Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus
- Dipeptidyl peptidaseโ4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin
- Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes
- Dipeptidyl peptidaseโ4 inhibitors and cardiovascular outcomes: metaโanalysis of randomized clinical trials with 55,141 participants
- Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: a meta-analysis
- Dipeptidylโpeptidaseโ4 inhibitors and pancreatic cancer: a cohort study
- Exposure to dipeptidylโpeptidaseโ4 inhibitors and COVIDโ19 among people with type 2 diabetes: a caseโcontrol study
- Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis
- Role of dipeptidyl peptidase 4 inhibitors in antidiabetic treatment
- Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials
- Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors
- Longer term safety of dipeptidyl peptidaseโ4 inhibitors in patients with type 2 diabetes mellitus: systematic review and metaโanalysis
- Dipeptidyl peptidase-4 inhibitors cause bullous pemphigoid in diabetic patients: report of two cases
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
- Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus
- The effects of dipeptidyl peptidaseโ4 inhibitors on kidney outcomes
- Dipeptidyl peptidase-4 inhibitors and osteoporosis
- Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis
- Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase
- Dipeptidyl peptidase 4 inhibitors: Applications in innate immunity?
- Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks?
- Dipeptidyl peptidaseโ4 inhibitors and sulfonylureas for type 2 diabetes: friend or foe?
- Dipeptidyl peptidaseโ4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLPโ1
- Impact of dipeptidyl-peptidase 4 inhibitors on cardiovascular diseases
- Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: a meta-analysis with trial sequential analysis
- Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study
- Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus
- Effect of dipeptidyl peptidase-4 inhibitors on heart failure: a meta-analysis of randomized clinical trials
- Association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors in patients with diabetes: estimating the risk of the new agents and characterizing the patients
- Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapyโfocus on alogliptin
- Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study
- Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture
- No significant association between dipeptidyl peptidase-4 inhibitors and adverse outcomes of COVID-19
- Dipeptidyl peptidaseโ4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment
- Dipeptidyl peptidaseโ4 inhibitors and HbA1c target of< 7% in type 2 diabetes: metaโanalysis of randomized controlled trials
- A case report of bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors
- Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus
- Effects on clinical outcomes of adding dipeptidyl peptidase-4 inhibitors versus sulfonylureas to metformin therapy in patients with type 2 diabetes mellitus
- Beneficial effects of dipeptidyl peptidase-4 inhibitors in diabetic Parkinson’s disease
- Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies
- Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors
- Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes
- Dipeptidyl peptidaseโ4 inhibitors attenuate endothelial function as evaluated by flowโmediated vasodilatation in type 2 diabetic patients
- The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
- Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortalityย โฆ
- Dipeptidyl peptidaseโ4 inhibitors and pancreatitis risk: a metaโanalysis of randomized clinical trials
- Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors
- Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment
- Dipeptidyl peptidase 4 (DPP-4) inhibitors and their role in Type 2 diabetes management
- Effect of dipeptidyl peptidase-4 inhibitors on bone metabolism and the possible underlying mechanisms
- Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis
- Dipeptidyl peptidase-4 inhibitors have protective effect on cognitive impairment in aged diabetic patients with mild cognitive impairment
- Can dipeptidyl peptidase-4 inhibitors treat cognitive disorders?
- Association between hospitalization for heart failure and dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: an observational study
- Sarcopenia in elderly diabetic patients: role of dipeptidyl peptidase 4 inhibitors
- Bullous pemphigoid associated with dipeptidyl peptidaseโ4 inhibitors: a report of five cases
- Is there an association between dipeptidyl peptidase-4 inhibitors and autoimmune disease? A population-based study
- Risk of dipeptidyl peptidaseโ4 (DPPโ4) inhibitors on siteโspecific cancer: A systematic review and metaโanalysis
- Efficacy and safety of dipeptidyl peptidaseโ4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: aย โฆ
- Bullous pemphigoid induced by dipeptidyl peptidaseโ4 inhibitors. Eight cases with clinical and immunological characterization
- Dipeptidyl peptidase 4 inhibitors in COVID-19: Beyond glycemic control
- Impact of comorbidities and glycemia at admission and dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes with COVID-19: a case series from anย โฆ
- Unique clinical and serological features of bullous pemphigoid associated with dipeptidyl peptidaseโ4 inhibitors
- Use of dipeptidyl peptidaseโ4 inhibitors and prognosis of COVIDโ19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADOย โฆ
- Dipeptidyl peptidase-4 inhibitors and fracture risk: an updated meta-analysis of randomized clinical trials
- Dipeptidyl peptidase-4 (DPP-4) inhibitors: promising new agents for autoimmune diabetes
- Dipeptidyl peptidaseโ4 inhibitors and preservation of pancreatic isletโcell function: a critical appraisal of the evidence
- The place of dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapeutics: a โme tooโ or โthe special oneโ antidiabetic class?
- Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis
- Effects of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type 2 diabetes: a systematic review and meta-analysis
- The role of dipeptidyl peptidaseโ4 inhibitors in diabetic kidney disease
- Recent advances in non-peptidomimetic dipeptidyl peptidase 4 inhibitors: medicinal chemistry and preclinical aspects
- โฆย of the binding properties, dipeptidyl peptidaseโ4 (DPPโ4) inhibitory activity and glucoseโlowering efficacy of the DPPโ4 inhibitors alogliptin, linagliptin, saxagliptinย โฆ
- Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials
- Comparative analysis of binding kinetics and thermodynamics of dipeptidyl peptidase-4 inhibitors and their relationship to structure
- Design, synthesis and anti-diabetic activity of triazolotriazine derivatives as dipeptidyl peptidase-4 (DPP-4) inhibitors
- Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and metaย โฆ
- Three cases of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors-one due to linagliptin
- Renal outcomes with dipeptidyl peptidase-4 inhibitors
- Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?
- Dipeptidyl peptidase-4 inhibitors can inhibit angiotensin converting enzyme
- โฆย therapies: highlighting common features and differences in the modes of action of glucagonโlike peptideโ1 receptor agonists and dipeptidyl peptidaseโ4 inhibitors
- Dipeptidyl peptidaseโ4 inhibitors can minimize the hypoglycaemic burden and enhance safety in elderly people with diabetes
- Bullous pemphigoid induced by dipeptidyl peptidase-4 (DPP-4) inhibitors: a pharmacovigilance-pharmacodynamic/pharmacokinetic assessment through an analysisย โฆ
- Dipeptidyl peptidase 4 inhibitors and the risk of bullous pemphigoid among patients with type 2 diabetes
- Dipeptidyl peptidase-4 inhibitors: Anti-diabetic drugs with potential effects on cancer
- A comprehensive review and perspective on natural sources as dipeptidyl peptidase-4 inhibitors for management of diabetes
- Dipeptidyl peptidase 4 inhibitors and the risk of cardiovascular disease in patients with type 2 diabetes: a tale of three studies
- Effects of dipeptidyl peptidase-4 inhibitors on renal outcomes in patients with type 2 diabetes: a systematic review and meta-analysis
- Pancreatitis and pancreatic cancer in patientes treated with Dipeptidyl Peptidase-4 inhibitors: An extensive and updated meta-analysis of randomized controlled trials
- Dipeptidyl peptidase 4 inhibitors reduce hepatocellular carcinoma by activating lymphocyte chemotaxis in mice
- Glycaemic efficacy of glucagonโlike peptideโ1 receptor agonists and dipeptidyl peptidaseโ4 inhibitors as addโon therapy to metformin in subjects with type 2 diabetesย โฆ
- Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidaseโ4 inhibitors and sulphonylureas: a primary careย โฆ
- Combination therapy of dipeptidyl peptidaseโ4 inhibitors and metformin in type 2 diabetes: rationale and evidence
- Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wideย โฆ
- Dipeptidyl peptidase-4 inhibitors and protection against stroke: A systematic review and meta-analysis
- Longโterm use of dipeptidyl peptidaseโ4 inhibitors and risk of fracture: a retrospective populationโbased cohort study
- The dipeptidylโpeptidaseโ4 (DPPโ4) inhibitors: a new class of oral therapy for patients with type 2 diabetes mellitus
- Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner
- Roles and mechanisms of dipeptidyl peptidase 4 inhibitors in vascular aging
- Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes
- Dipeptidyl-peptidase-4 inhibitors and heart failure: class effect, substance-specific effect, or chance effect?
- Effect of dipeptidyl peptidase 4 inhibitors on acute and subacute models of inflammation in male Wistar rats: an experimental study
- The pleiotropic cardiovascular effects of dipeptidyl peptidaseโ4 inhibitors
- The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials
- Dipeptidyl peptidaseโ4 inhibitorsโassociated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients
- Cost-effectiveness analysis of metformin+ dipeptidyl peptidase-4 inhibitors compared to metformin+ sulfonylureas for treatment of type 2 diabetes
- Dipeptidyl peptidase-4 inhibitors and risk of arthralgia: a systematic review and meta-analysis
- Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes
- Dipeptidyl peptidase-4 inhibitors in chronic kidney disease: a systematic review of randomized clinical trials
- The effect of dipeptidyl peptidase-4 inhibitors on macrovascular and microvascular complications of diabetes mellitus: a systematic review
- Diabetes: Rationale for Dipeptidyl Peptidase 4 Inhibitors: A New Class of Oral Agents for the Treatment of Type 2 Diabetes Mellitus
- Serum and adipose dipeptidyl peptidase 4 in cardiovascular surgery patients: influence of dipeptidyl peptidase 4 inhibitors
- Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabetes mellitus
- Gastrointestinal adverse events of dipeptidyl peptidase 4 inhibitors in type 2 diabetes: a systematic review and network meta-analysis
- Effectiveness and safety of sodiumโglucose coโtransporterโ2 inhibitors compared with dipeptidyl peptidaseโ4 inhibitors in older adults with type 2 diabetes: Aย โฆ
- Dipeptidyl peptidase 4 inhibitors attenuates the decline of skeletal muscle mass in patients with type 2 diabetes
- Dipeptidyl peptidaseโ4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: a nationwide populationโbased cohort study
- Effects of dipeptidyl peptidase 4 inhibitors and sodium-glucose linked cotransporter-2 inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: aย โฆ
- Dipeptidyl peptidaseโ4 inhibitors, glucagonโlike peptide 1 receptor agonists and sodiumโglucose coโtransporterโ2 inhibitors for people with cardiovascular disease: aย โฆ
- The safety of dipeptidyl peptidaseโ4 (DPPโ4) inhibitors or sodiumโglucose cotransporter 2 (SGLTโ2) inhibitors added to metformin background therapy in patients withย โฆ
- Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germanyโa retrospective analysis of real-world data
- Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials
- Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials
- Dipeptidyl peptidase-4 inhibitors and diabetic kidney disease: a narrative review
- Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of cardiovascular outcome trials
- Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials
- Effect of dipeptidyl peptidase-4 inhibitors on heart failure: a network meta-analysis
- The association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors: a ten-year prospective observational study
- Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials
- Dipeptidyl peptidaseโ4 inhibitors and bullous pemphigoid: A systematic review and adjusted metaโanalysis
- Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with moderate to severe renal impairment: a systematic review andย โฆ
- Heart failure and dipeptidyl peptidaseโ4 inhibitors
- Safety of dipeptidyl peptidase 4 inhibitors for treatment of type 2 diabetes
- Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial
- A review on cardiovascular outcome studies of dipeptidyl peptidase-4 inhibitors
- Do dipeptidyl peptidase-4 inhibitors increase the risk of heart failure?
- Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agents
- Dipeptidyl peptidaseโ4 inhibitors moderate the risk of genitourinary tract infections associated with sodiumโglucose coโtransporterโ2 inhibitors
- Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study
- Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: An extensive meta-analysis of randomizedย โฆ
- Dipeptidyl peptidase-4 inhibitors and risk of heart failure in patients with type 2 diabetes mellitus: a population-based cohort study
- QSAR study of dipeptidyl peptidase-4 inhibitors based on the Monte Carlo method
- Dipeptidyl peptidase 4 inhibitors as novel agents in improving survival in diabetic patients with colorectal cancer and lung cancer: A Surveillance Epidemiology andย โฆ
- Have dipeptidyl peptidase-4 inhibitors ameliorated the vascular complications of type 2 diabetes in large-scale trials? The potential confounding effect of stemย โฆ
- Bullous pemphigoid and dipeptidyl peptidase 4 inhibitors: a disproportionality analysis based on the Japanese adverse drug event report database
- Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy
- Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes
- Oral diabetes medications other than dipeptidyl peptidase 4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study
- Mechanisms of neurodegeration in type 2 diabetes and the neuroprotective potential of dipeptidyl peptidase 4 inhibitors
- Efficacy and safety of sodiumโglucose cotransporterโ2 inhibitors versus dipeptidyl peptidaseโ4 inhibitors as monotherapy or addโon to metformin in patients with typeย โฆ
- Comparative safety of dipeptidyl peptidaseโ4 inhibitors and sulfonylureas among frail older adults
- Effects of dipeptidyl peptidaseโ4 inhibitors and sulphonylureas on cognitive and physical function in nursing home residents
- Dipeptidyl peptidase-4 inhibitors and COVID-19-related deaths among patients with type 2 diabetes mellitus: a meta-analysis of observational studies
- Lower cardiorenal risk with sodiumโglucose cotransporterโ2 inhibitors versus dipeptidyl peptidaseโ4 inhibitors in patients with type 2 diabetes without cardiovascularย โฆ
- Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world useย โฆ
- Comparative safety of dipeptidyl peptidase-4 inhibitors versus sulfonylureas and other glucose-lowering therapies for three acute outcomes
- Dipeptidyl peptidase-4 inhibitors attenuates osteoporosis in patients with diabetes: a nationwide, retrospective, matched-cohort study in Taiwan
- Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting
- Bullous pemphigoid with dipeptidyl peptidaseโ4 inhibitors: Clinical features and pathophysiology
- Emerging roles of dipeptidyl peptidase-4 inhibitors in delaying the progression of type 1 diabetes mellitus
- Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis
- Comparative safety of sodiumโglucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors and sulfonylureas on the risk of diabetic ketoacidosis
- The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes
- The emerging role of dipeptidyl peptidase-4 inhibitors in cardiovascular protection: current position and perspectives
- Navigating the chemical space of dipeptidyl peptidase-4 inhibitors
- Mechanism by which dipeptidyl peptidase-4 inhibitors increase the risk of heart failure and possible differences in heart failure risk
- Use of dipeptidyl-peptidase-4 inhibitors and the risk of pneumonia: a population-based cohort study
- Increased risk of bullous pemphigoid in dipeptidyl peptidase 4 inhibitors: a nationwide, populationโbased, cohort study in Taiwan
- Predictive factors for efficacy of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus
- Wound healing effects of dipeptidyl peptidase-4 inhibitors: an emerging concept in management of diabetic foot ulcerโa review
- โฆย -onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors
- The effects of dipeptidyl peptidase-4 inhibitors on cardiovascular disease risks in type 2 diabetes mellitus
- Dipeptidyl peptidase-4 inhibitors, peripheral arterial disease, and lower extremity amputation risk in diabetic patients
- Direct headโtoโhead comparison of glycaemic durability of dipeptidyl peptidaseโ4 inhibitors and sulphonylureas in patients with type 2 diabetes mellitus: A metaย โฆ
- Dipeptidyl peptidase 4 (DPP-4) inhibitors and the risk of lung cancer: Current evidence and future directions
- Effects of dipeptidyl peptidase-4 inhibitors on cardiac and endothelial function in type 2 diabetes mellitus: A pilot study
- โฆย ), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors
- Addition of dipeptidyl peptidaseโ4 inhibitors to insulin treatment in type 2 diabetes patients: a metaโanalysis
- Dipeptidyl peptidase-4 inhibitors: a new approach in diabetes treatment
- Dipeptidyl peptidase-4 inhibitors and their potential role in the management of atherosclerosisโA review
- The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: a network meta-analysis of randomizedย โฆ
- Nationwide trends in pancreatitis and pancreatic cancer risk among patients with newly diagnosed type 2 diabetes receiving dipeptidyl peptidase 4 inhibitors
- Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetesย โฆ
- Pharmacology of dipeptidyl peptidase-4 inhibitors and its use in the management of metabolic syndrome: a comprehensive review on drug repositioning
- Combination of vitamin D and dipeptidyl peptidase-4 inhibitors (VIDPP-4i) as an immunomodulation therapy for autoimmune diabetes
- Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: systematic review andย โฆ
- Association of hemoglobin A1c levels with use of sulfonylureas, dipeptidyl peptidase 4 inhibitors, and thiazolidinediones in patients with type 2 diabetes treated withย โฆ
- โฆย antiโinflammatory properties of glucagonโlike peptideโ1, glucoseโdependent insulinotropic polypepide, and dipeptidyl peptidaseโ4 inhibitors in experimental animals
- Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized controlled trials
- Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system
- Dipeptidyl peptidaseโ4 inhibitors and angioedema: a class effect?
- Dipeptidyl peptidase-4 inhibitors reduced long-term cardiovascular risk in diabetic patients after percutaneous coronary intervention via insulin-like growthย โฆ
- Dipeptidyl peptidase-4 inhibitors and inflammatory bowel disease risk: a meta-analysis
- Dipeptidyl peptidase 4 inhibitors decrease the risk of hepatocellular carcinoma in patients with chronic hepatitis C infection and type 2 diabetes mellitus: aย โฆ
- Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors: a population-based nested case-control study
- Cardiovascular effects of dipeptidyl peptidase-4 inhibitors
- The safety of dipeptidyl peptidase 4 inhibitors and the risk for heart failure
- Effect of dipeptidyl peptidase-4 inhibitors on postprandial glucagon level in patients with type 2 diabetes mellitus: A systemic review and meta-analysis
- Dipeptidyl peptidase-4 inhibitors and heart failure: analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System
- Associations of dipeptidyl peptidaseโ4 inhibitors with mortality in hospitalized heart failure patients with diabetes mellitus
- Detection and characterization of IgG, IgE, and IgA autoantibodies in patients with bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors
- Effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic retinopathy and its progression: A real-world Koreanย โฆ
- Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis
- Protective effects of dipeptidyl peptidase-4 inhibitors on progression of diabetic retinopathy in patients with type 2 diabetes
- โฆย between the dipeptidyl peptidase-4 and stromal cell-derived factor-1 in stem cell homing and myocardial repair: potential impact of dipeptidyl peptidase-4 inhibitors
- Dipeptidyl peptidase-4 inhibitors in cardioprotection: a promising therapeutic approach
- Use of dipeptidyl peptidase-4 inhibitors for the treatment of patients with type 2 diabetes mellitus and chronic kidney disease
- Cardioprotective effects of dipeptidyl peptidase-4 inhibitors versus sulfonylureas in addition to metformin: a nationwide cohort study of patients with type 2 diabetes
- SARS-CoV-2 and diabetes: A potential therapeutic effect of dipeptidyl peptidase 4 inhibitors in diabetic patients diagnosed with COVID-19
- โฆย , molecular simulation, and biological activities of novel quinazolinone-pyrimidine hybrid derivatives as dipeptidyl peptidase-4 inhibitors and anticancer agents
- Effectiveness and safety of dipeptidyl peptidase 4 inhibitors in the management of type 2 diabetes in older adults: a systematic review and development ofย โฆ
- The risk of fragility fractures in new users of dipeptidyl peptidase-4 inhibitors compared to sulfonylureas and other anti-diabetic drugs: a cohort study
- Dipeptidyl peptidase-4 inhibitors and the risks of autoimmune diseases in type 2 diabetes mellitus patients in Taiwan: a nationwide population-based cohortย โฆ
- Bullous pemphigoid associated with dipeptidyl peptidaseโ4 inhibitors. A case series and analysis of cases reported in the Spanish pharmacovigilance database
- Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study inย โฆ
- Cardiovascular safety of dipeptidyl peptidase-4 inhibitors: recent evidence on heart failure
- Neuroprotection by dipeptidyl-peptidase-4 inhibitors and glucagon-like peptide-1 analogs via the modulation of AKT-signaling pathway in Alzheimer’s disease
- โฆย -glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and dipeptidyl peptidase-4 (DPP-4) inhibitors: a systematic review
- Association between the use of dipeptidyl peptidase 4 inhibitors and the risk of dementia among patients with type 2 diabetes in Taiwan
- Emerging roles of dipeptidyl peptidase 4 inhibitors: anti-inflammatory and immunomodulatory effect and its application in diabetes mellitus
- Effects of dipeptidyl peptidaseโ4 inhibitors on transforming growth factorโฮฒ1 signal transduction pathways in the ovarian fibrosis of polycystic ovary syndrome rats
- Persistence to treatment with novel antidiabetic drugs (dipeptidyl peptidase-4 inhibitors, sodium-glucose co-transporter-2 inhibitors, and glucagon-like peptideย โฆ
- Ethnic difference in the pharmacodynamicsโefficacy relationship of dipeptidyl peptidaseโ4 inhibitors between Japanese and nonโJapanese patients: a systematicย โฆ
- Use of dipeptidyl peptidase 4 inhibitors and fracture risk compared to use of other antiโhyperglycemic drugs
- Comparative cardiovascular risks of dipeptidyl peptidase 4 inhibitors with other secondโand thirdโline antidiabetic drugs in patients with type 2 diabetes
- The effect of metformin or dipeptidyl peptidase 4 inhibitors on clinical outcomes in metastatic nonโsmall cell lung cancer treated with immune checkpoint inhibitors
- Effect of dipeptidyl peptidaseโ4 inhibitors on complement activation
- Protective effect of dipeptidyl peptidase-4 inhibitors in testicular torsion/detorsion in rats: a possible role of HIF-1ฮฑ and nitric oxide
- Dipeptidyl peptidase-4 inhibitors and cardiovascular events in patients with type 2 diabetes, without cardiovascular or renal disease
- Effects of dipeptidyl peptidase-4 inhibitors on hyperglycemia and blood cyclosporine levels in renal transplant patients with diabetes: a pilot study
- Restoration of the insulinotropic effect of glucoseโdependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidaseโ4 inhibitors
- Dipeptidyl peptidase-4 inhibitors and cardiovascular risks in patients with pre-existing heart failure
- Safety and effectiveness of dipeptidyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failing two oralย โฆ
- Pharmacovigilance study of the association between dipeptidyl peptidaseโ4 inhibitors and angioedema using the FDA Adverse Event Reporting Systemย โฆ
- Molecular docking study on dipeptidyl peptidase-4 inhibitors
- No increased risk of hospitalization for heart failure for patients treated with dipeptidyl peptidase-4 inhibitors in Taiwan
- Efficacy of glucagonโlike peptideโ1 receptor agonists compared to dipeptidyl peptidaseโ4 inhibitors for the management of type 2 diabetes: A metaโanalysis ofย โฆ
- 3D-QSAR studies of dipeptidyl peptidase-4 inhibitors using various alignment methods
- Safety of dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
- Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis ofย โฆ
- Meta-analysis of dipeptidyl peptidase-4 inhibitors use and cardiovascular risk in patients with type 2 diabetes mellitus
- Association of adverse respiratory events with sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors among patients with type 2ย โฆ
- Headโtoโhead comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury
- Exposure to dipeptidylโpeptidase 4 inhibitors and the risk of pneumonia among people with type 2 diabetes: retrospective cohort study and metaโanalysis
- โฆย of hospitalization for heart failure, kidney disease and death with sodiumโglucose coโtransporterโ2 inhibitors compared with dipeptidyl peptidaseโ4 inhibitors in type 2ย โฆ
- Pharmacogenetics of dipeptidyl peptidase 4 inhibitors in a Taiwanese population with type 2 diabetes
- Trends in antidiabetic prescription patterns in Japan from 2005 to 2011 Impact of the introduction of dipeptidyl peptidase-4 inhibitors
- Efficacy of different dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters in patients with type 2 diabetes undergoing dialysis
- Potential for combination of dipeptidyl peptidaseโ4 inhibitors and sodiumโglucose coโtransporterโ2 inhibitors for the treatment of type 2 diabetes
- No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidaseโ4 inhibitors vs therapeutic alternatives
- A safety and tolerability profile comparison between dipeptidyl peptidase-4 inhibitors and sulfonylureas in diabetic patients: A systematic review and meta-analysis
- Comparative cardiovascular risks of dipeptidyl peptidase-4 inhibitors: analyses of real-world data in Korea
- Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus
- Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus
- Dipeptidyl peptidase-4 inhibitors in progressive kidney disease
- Identification of levomenthol derivatives as potential dipeptidyl peptidase-4 inhibitors: a comparative study with gliptins
- The roles of dipeptidyl peptidase-4 inhibitors in prognosis of COVID-19 infection in patients with type 2 diabetes mellitus
- Association between dipeptidyl peptidase-4 inhibitors and risk of bullous pemphigoid in patients with type 2 diabetes: a population-based cohort study
- Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes
- Action of dipeptidyl peptidaseโ4 inhibitors on SARSโCoVโ2 main protease
- A fluorescent switchable AIE probe for selective imaging of dipeptidyl peptidase-4 in vitro and in vivo and its application in screening DPP-4 inhibitors
- Dipeptidyl peptidase-4 inhibitors for the potential treatment of brain disorders; a mini-review with special focus on linagliptin and stroke
- Effect of dipeptidyl peptidase-4 inhibitors on the risk of bone fractures in a Korean population
- Use of dipeptidyl peptidase-4 inhibitors and new-onset rheumatoid arthritis in patients with type 2 diabetes
- Influence of dipeptidyl peptidase-4 inhibitors on glycemic variability in patients with type 2 diabetes: A meta-analysis of randomized controlled trials
- Real-world adherence, persistence, and in-class switching during use of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis involving 594,138ย โฆ
- Comparison of dipeptidyl peptidase-4 inhibitors and pioglitazone combination therapy versus pioglitazone monotherapy in type 2 diabetes: a system reviewย โฆ
- Dipeptidyl Peptidase-4 Inhibitors and the Risk of Heart Failure: Regression to the Truth?
- Dipeptidyl peptidase-4 inhibitors and the risk of acute pancreatitis in patients with type 2 diabetes in Taiwan: a population-based cohort study
- Caveolin-1, a binding protein of CD26, is essential for the anti-inflammatory effects of dipeptidyl peptidase-4 inhibitors on human and mouse macrophages
- Adherence, persistence, and health care costs for patients receiving dipeptidyl peptidase-4 inhibitors
- โฆย risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide populationย โฆ
- Licochalcone A Derivatives as Selective Dipeptidyl Peptidase 4 Inhibitors with Anti-Inflammatory Effects
- Dipeptidyl peptidase-4 inhibitors as new tools for cardioprotection
- Structureโactivity relationship analysis of cocrystallized gliptin-like pyrrolidine, trifluorophenyl, and pyrimidine-2, 4-dione dipeptidyl peptidase-4 inhibitors
- Effect of dipeptidyl peptidase-4 inhibitors on plasma adiponectin: A systematic review and meta-analysis of randomized controlled trials
- Factors contributing to the adverse drug reactions associated with the dipeptidyl peptidase-4 (DPP-4) inhibitors: A scoping review
- Dipeptidyl peptidase-4 inhibitors and their effects on the cardiovascular system
- Dipeptidyl Peptidase-4 inhibitors use in type II diabetic patients in a tertiary hospital
- Virtual screening of dipeptidyl peptidase-4 inhibitors using quantitative structureโactivity relationship-based artificial intelligence and molecular docking of hitย โฆ
- Switching dipeptidyl peptidase-4 inhibitors to tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2 improve arterial stiffness evaluated by cardio-ankleย โฆ
- Assessment of the risk of hospitalization for heart failure with dipeptidyl peptidase-4 inhibitors, saxagliptin, alogliptin, and sitagliptin in patients with type 2 diabetesย โฆ
- Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients withย โฆ
- The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety
- Comparative renal effects of dipeptidyl peptidase-4 inhibitors and sodium-glucose cotransporter 2 inhibitors on individual outcomes in patients with type 2ย โฆ
- Effect of dipeptidyl-peptidase-4 inhibitors on C-reactive protein in patients with type 2 diabetes: a systematic review and meta-analysis
- Efficacy and safety of dipeptidyl peptidaseโ4 inhibitors as an addโon to insulin treatment in patients with type 2 diabetes: a review
- Effect of resveratrol on dipeptidyl peptidase-4 inhibitors pharmacokinetics: An in vitro and in vivo approach
- Efficacy and safety of Dipeptidyl Peptidase-4 Inhibitors in kidney transplant recipients with Post-transplant diabetes mellitus (PTDM)-a systematic review and Metaย โฆ
- Context-dependent effects of dipeptidyl peptidase 4 inhibitors
- Effect of dipeptidyl peptidase-4 inhibitors on circulating tumor necrosis factor-ฮฑ concentrations: a systematic review and meta-analysis of controlled trials
- Dipeptidyl peptidaseโ4 inhibitors as preferable oral hypoglycemic agents in terms of treatment satisfaction: results from a multicenter, 12โweek, open labelย โฆ
- Combination therapy with once-weekly glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a case series
- Enzymatic release of dipeptidyl peptidaseโ4 inhibitors (gliptins) from pigeon pea (Cajanus cajan) nutrient reservoir proteins: In silico and in vitro assessments
- Dipeptidyl peptidase-4 inhibitors (DPP-4i) combined with vitamin D3: An exploration to treat new-onset type 1 diabetes mellitus and latent autoimmune diabetes inย โฆ
- Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asiaย โฆ
- Costโutility analysis of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine hagedorn basal insulin as addย โฆ
- โฆย reduction in chronic kidney disease progression with sodiumโglucose cotransporterโ2 inhibitors compared to dipeptidyl peptidaseโ4 inhibitors in adults with type 2ย โฆ
- Association of dipeptidyl peptidase 4 inhibitors with risk of metastases in patients with type 2 diabetes and breast, prostate or digestive system cancer
- Lipoprotein effects of incretin analogs and dipeptidyl peptidase 4 inhibitors
- Dipeptidyl peptidase-4 inhibitors and bone metabolism: is vitamin D the link?
- Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin
- Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors
- Effect of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase 4 inhibitors on cardiovascular function in patients with type 2 diabetes mellitusย โฆ
- โฆย treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohortย โฆ
- โฆย -Product-Derived 2-Phenyl-3,4-dihydro-2H-benzo[f]chromen-3-amine Analogs as Novel and Potent Dipeptidyl Peptidase 4 (DPP-4) Inhibitors for the Treatment ofย โฆ
- Dipeptidyl peptidase-4 inhibitors have adverse effects for the proliferation of human T cells
- Association between dipeptidyl peptidaseโ4 inhibitors and urinary tract infection in elderly patients: A retrospective cohort study
- Dipeptidyl peptidase 4 inhibitors attenuate cardiac ischaemiaโreperfusion injury in rats with diabetes mellitus type 2
- Incorporating incretin-based therapies into clinical practice: differences between glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors
- Re-evaluation of dipeptidyl peptidase-4 inhibitors in patients with heart failure and diabetes mellitus
- Myocardial infarction in type 2 diabetes using sodiumโglucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptorย โฆ
- Predicting efficacy of dipeptidyl peptidaseโ4 inhibitors in patients with type 2 diabetes: association of glycated hemoglobin reduction with serum eicosapentaenoicย โฆ
- Cardiovascular outcomes of dipeptidyl peptidase-4 inhibitors in elderly patients with type 2 diabetes: a nationwide study
- Dipeptidyl peptidase-4 inhibitors are associated with improved left ventricular diastolic function after acute myocardial infarction in diabetic patients
- Meta-analysis of the cardiovascular outcomes with dipeptidyl peptidase 4 inhibitors: validation of the current FDA mandate
- Discovery of novel 1, 3, 5-triazine-thiazolidine-2, 4-diones as dipeptidyl peptidase-4 inhibitors with antibacterial activity targeting the S1 pocket for the treatment of typeย โฆ
- Treatment discontinuation and clinical events in type 2 diabetes patients treated with dipeptidyl peptidase-4 inhibitors or NPH insulin as third-line therapy
- Choosing dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter-2 inhibitors, or both, as add-ons to metformin: patient baseline characteristics are crucial
- Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues usingย โฆ
- Dipeptidyl peptidase 4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus
- Bicyclic cyanothiazolidines as novel dipeptidyl peptidase 4 inhibitors
- Renoprotective effect of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus
- Dipeptidyl peptidase-4 inhibitors and sulfonylureas prevent the progressive impairment of the nigrostriatal dopaminergic system induced by diabetes during aging
- Beneficial effects of dipeptidyl peptidase-4 inhibitors on heart failure with preserved ejection fraction and diabetes
- Dipeptidyl peptidase 4 inhibitors and risk of inflammatory bowel disease among patients with type 2 diabetes: a meta-analysis of randomized controlled trials
- Dipeptidyl peptidaseโ4 inhibitors and the risk of communityโacquired pneumonia in patients with type 2 diabetes
- Acarbose with comparable glucose-lowering but superior weight-loss efficacy to dipeptidyl peptidase-4 inhibitors: a systematic review and network metaย โฆ
- Increased risk of hospitalization for heart failure with newly prescribed dipeptidyl peptidase-4 inhibitors and pioglitazone using the Korean Health Insuranceย โฆ
- โฆย patients with type 2 diabetes after percutaneous coronary intervention and treated with sodiumโglucose cotransporter 2 inhibitors vs. dipeptidyl peptidase-4 inhibitors
- Dipeptidyl peptidase-4 inhibitors in diverse patient populations with type 2 diabetes
- Finding the most cost-effective option from commonly used Dipeptidyl peptidase-4 inhibitors in India: a systematic study
- Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials
- Dipeptidyl peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus
- Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists
- Real-world evaluation of glycemic control among patients with type 2 diabetes mellitus treated with canagliflozin versus dipeptidyl peptidase-4 inhibitors
- Prior treatment with dipeptidyl peptidase 4 inhibitors is associated with better functional outcome and lower in-hospital mortality in patients with type 2 diabetesย โฆ
- Clinical characteristics of the responders to dipeptidyl peptidase-4 inhibitors in Korean subjects with type 2 diabetes
- Dipeptidyl peptidase-4 inhibitors and the risk of pancreatitis in patients with type 2 diabetes mellitus: a population-based cohort study
- Effect of dipeptidyl peptidase-4 inhibitors on cisplatin-induced acute nephrotoxicity in cancer patients with diabetes mellitus: A retrospective study
- Quality-of-life comparison of dapagliflozin versus dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes mellitus: A randomized controlled trial (Jย โฆ
- โฆย and structureโactivity relationship exploration of uracil-based benzoic acid and ester derivatives as novel dipeptidyl Peptidase-4 inhibitors for the treatment of type 2ย โฆ
- The assessment of the efficacy of dipeptidyl peptidase-4 inhibitors in patients with glucocorticoid-induced diabetes by continuous glucose monitoring
- Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation
- Role of dipeptidyl peptidase-4 inhibitors in patients with diabetes infected with coronavirus-19
- Lisinopril prevents bullous pemphigoid induced by dipeptidyl peptidase 4 inhibitors via the Mas receptor pathway
- Cardiovascular risks associated with dipeptidyl peptidaseโ4 inhibitors monotherapy compared with other antidiabetes drugs in the Japanese population: a nationwideย โฆ
- Effect of dipeptidyl-peptidase 4 inhibitors on circulating oxidative stress biomarkers in patients with type 2 diabetes mellitus
- Defining dipeptidyl peptidaseโ4 inhibitorsโrelated bullous pemphigoid: A singleโcentre retrospective study
- Non-Specific Inhibition of Dipeptidyl Peptidases 8/9 by Dipeptidyl Peptidase 4 Inhibitors Negatively Affects Mesenchymal Stem Cell Differentiation
- Dipeptidyl peptidase-4 inhibitors versus other antidiabetic drugs added to metformin monotherapy in diabetic retinopathy progression: a real world-basedย โฆ
- Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes
- The efficacy and safety of dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus patients with severe renal impairment: a meta-analysis
- Cardiovascular safety signals with dipeptidyl peptidaseโ4 inhibitors: A disproportionality analysis among highโrisk patients
- Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) agonists: no
- Dipeptidyl Peptidase-4 Inhibitors and Inflammation: Dpp-4 Inhibitors Improve Mean Pleatelet Volume and Gamma Glutamyl Transferase Level
- Effect of switching to teneligliptin from other dipeptidyl peptidaseโ4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidneyย โฆ
- The effects of dipeptidyl peptidase-4 inhibitors in treatment of obese patients with type 2 diabetes
- Dipeptidyl-peptidase-4 inhibitors in type 2 diabetes and COVID-19: from a potential repurposed agent to a useful treatment option
- Sodiumโglucose coโtransporterโ2 inhibitors versus dipeptidyl peptidaseโ4 inhibitors and the risk of heart failure: A nationwide cohort study of older adults withย โฆ
- Lessons learned from cardiovascular outcome clinical trials with dipeptidyl peptidase 4 (DPP-4) inhibitors
- Evaluation of treatment satisfaction, efficacy and safety of dipeptidyl peptidase-4 inhibitors in geriatric patients with type 2 diabetes mellitus: A crossย โฆ
- Comparative effects of metformin and dipeptidyl peptidase-4 inhibitors in japanese obese patients with type 2 diabetes: a claims database study
- Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus
- Pharmacoeconomic evaluation of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus: a systematic literature review
- Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
- โฆย risk factors between patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors: a meta-analysis
- The role of dipeptidyl peptidase-4 inhibitors
- The effects of dipeptidyl peptidase 4 inhibitors on renal function in patients with type 2 diabetes mellitus
- Persistent whole day meal effects of three dipeptidyl peptidaseโ4 inhibitors on glycaemia and hormonal responses in metforminโtreated type 2 diabetes
- Factors associated with switching from sulphonylureas to dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in the United States
- Cardiovascular safety of empagliflozin versus dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetes: systematic literature review and indirectย โฆ
- Cardiovascular outcomes associated with prescription of sodiumโglucose coโtransporterโ2 inhibitors versus dipeptidyl peptidaseโ4 inhibitors in patients with diabetesย โฆ
- Lower COVID-19 mortality in patients with type 2 diabetes mellitus taking dipeptidyl peptidase-4 inhibitors: results from a Turkish nationwide study
- Comparison of the effects on cardiovascular events between use of metformin and dipeptidyl peptidase-4 inhibitors as the first-line hypoglycaemic agents inย โฆ
- A multi-center retrospective analysis examining the effect of dipeptidyl peptidase-4 inhibitors on progression-free survival in patients with prostate cancer
- Comparisons between dipeptidyl peptidase-4 inhibitors and other classes of hypoglycemic drugs using two distinct biomarkers of pancreatic beta-cell functionย โฆ
- Real-world comparison of mono and dual combination therapies of metformin, sulfonylurea, and dipeptidyl peptidase-4 inhibitors using a common data modelย โฆ
- Discovery of potent, selective, and orally bioavailable pyridone-based dipeptidyl peptidase-4 inhibitors
- Potential anti-atherosclerotic effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus
- Incretinโbased treatment of type 2 diabetes: glucagonโlike peptideโ1 receptor agonists and dipeptidyl peptidaseโ4 inhibitors
- โฆย Adding SodiumโGlucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Studyย โฆ
- Play of chance versus concerns regarding dipeptidyl peptidase-4 inhibitors: heart failure and diabetes
- Changes in medication adherence and unused drugs after switching from daily dipeptidyl peptidase-4 inhibitors to once-weekly trelagliptin in patients with type 2ย โฆ
- Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors
- Association between use of dipeptidyl peptidase-4 inhibitors and the risk of acute kidney injury: a nested case-control study
- โฆย making framework for medicine purchasing in Chinese public hospital decision-making: determining the value of five dipeptidyl peptidase 4 (DPP-4) inhibitors
- Synthesis and biological evaluation of novel benzyl-substituted (S)-phenylalanine derivatives as potent dipeptidyl peptidase 4 inhibitors
- Systematic review and meta-analysis: dipeptidyl peptidase-4 inhibitors and rheumatoid arthritis risk
- Structure-based virtual screening of dipeptidyl peptidase 4 inhibitors and their in vitro analysis
- The effects of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide 1 receptor agonists on cognitive functions in adults with type 2 diabetes mellitus: a systematicย โฆ
- Tissue distribution of teneligliptin in rats and comparisons with data reported for other dipeptidyl peptidaseโ4 inhibitors
- The effects of switching from dipeptidyl peptidase-4 Inhibitors to Glucagon-Like Peptide-1 receptor agonists on bone mineral density in diabetic patients
- Sodium-Glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors, and risk of hospitalization
- Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidaseโ4 inhibitors: Real world evidence fromย โฆ
- The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: a retrospective study
- Systematic review and meta-analysis of efficacy and safety of combinational therapy with metformin and dipeptidyl peptidase-4 inhibitors
- Dipeptidyl peptidase-4 (DPP-4) inhibitors
- Risk of hospitalization with sodiumโglucose cotransporterโ2 inhibitors versus dipeptidyl peptidaseโ4 inhibitors in patients with type 2 diabetes lacking evidence ofย โฆ
- Differential effects of thiazolidinediones and dipeptidyl peptidase-4 inhibitors on insulin resistance and ฮฒ-cell function in type 2 diabetes mellitus: a propensityย โฆ
- Efficacy and safety of switching to teneligliptin in patients with type 2 diabetes inadequately controlled with dipeptidyl peptidase-4 inhibitors: a 12-week interimย โฆ
- Sodium-glucose cotransporter 2 (SGLT2) inhibitors vs. dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset dementia: a propensity score-matchedย โฆ
- โฆย preservation, comparing patients receiving sodiumโglucose coโtransporterโ2 inhibitors with those receiving dipeptidyl peptidaseโ4 inhibitors, using a supervisedย โฆ
- โฆย co-transporter 2 inhibitors may change the development of urinary tract and hematological malignancies as compared with dipeptidyl peptidase-4 inhibitorsย โฆ
- Review on the effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of non-alcoholic fatty liver disease
- โฆย epidemiology of ketosis and low bicarbonate concentration in inpatients treated with sodium-glucose linked cotransporter inhibitors or dipeptidyl peptidase-4 inhibitors
- An updated systematic review and meta-analysis on the efficacy and tolerability of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes with moderate toย โฆ
- Renoprotection provided by dipeptidyl peptidase-4 inhibitors in combination with angiotensin receptor blockers in patients with type 2 diabetic nephropathy
- Use of dipeptidyl peptidase-4 inhibitors is associated with a lower risk of rheumatoid arthritis in patients with type 2 diabetes mellitus: A systematic review and metaย โฆ
- Factors related to the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis focusing on ethnicity and study regions
- Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Labelย โฆ
- Urate-lowering effects of dipeptidyl peptidase-4 inhibitors
- Effect of switching from linagliptin to teneligliptin dipeptidyl peptidase-4 inhibitors in older patients with type 2 diabetes mellitus
- Association of Dipeptidyl Peptidase-4 Inhibitors Use with Reduced Risk of Hepatocellular Carcinoma in Type 2 Diabetes Patients with Chronic HBV Infection
- Dipeptidyl Peptidase-4 Inhibitors and Cardiovascular Outcome
- Costโeffectiveness of sodiumโglucose cotransporterโ2 inhibitors versus dipeptidyl peptidaseโ4 inhibitors among patients with type 2 diabetes with and withoutย โฆ
- Comparing treatment intensification and clinical outcomes of metformin and dipeptidyl peptidaseโ4 inhibitors in treatmentโnaรฏve patients with type 2 diabetes in Japan
- โฆย rosiglitazone’s black box warning and restricted access program on the uptake of thiazolidinediones and dipeptidyl peptidase-4 inhibitors among patients with type 2ย โฆ
- Sodiumโglucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on newโonset overall cancer in Type 2 diabetes mellitus: A populationโbased study
- Dipeptidyl peptidaseโ4 inhibitors and prevention of bone fractures: Effects beyond glyemic control
- โฆย patients with type 2 diabetes mellitus who do not respond to incretin-based therapies including glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors
- Risk heterogeneity of bullous pemphigoid among dipeptidyl peptidaseโ4 inhibitors: A populationโbased cohort study using Japanese LatterโStage Elderly Healthcareย โฆ
- Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, and Sodium-Glucose Cotransporter-2 Inhibitors and COVID-19 Outcomes
- Association of Genetic Variants of HLA-DQA1 with Bullous Pemphigoid Induced by Dipeptidyl Peptidase-4 Inhibitors
- Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcome and Cardiac Function in Patients With Diabetes and Heart FailureโInsights From the Ibarakiย โฆ
- Impact of metformin use on the cardiovascular effects of dipeptidyl peptidaseโ4 inhibitors: An analysis of Medicare claims data from 2007 to 2015
- Synthesis and biological evaluation of pyrrolidine-2-carbonitrile and 4-fluoropyrrolidine-2-carbonitrile derivatives as dipeptidyl peptidase-4 inhibitors for the treatmentย โฆ
- Design, synthesis, and pharmacological evaluation of highly potent and selective dipeptidyl peptidaseโ4 inhibitors
- Effect of Dipeptidyl Peptidase-4 Inhibitors vs. Metformin on Major Cardiovascular Events Using Spontaneous Reporting System and Real-World Database Study
- Pemphigoid nodularis induced by long-term use of dipeptidyl peptidase-4 inhibitors
- Head-to-Head comparison of the hypoglycemic efficacy and safety between dipeptidyl peptidase-4 inhibitors and ฮฑ-glucosidase inhibitors in patients with typeย โฆ
- Dipeptidyl Peptidase 4 Inhibitors and Gallbladder or Biliary Diseases: Data From the US Food and Drug Administration Adverse Event Reporting System
- Dipeptidyl peptidase 4 (DPP4) inhibitors stride up the management of Parkinson’s disease
- Dipeptidyl-Peptidase 4 Inhibitors did not Improve Renal Endpoints in Advanced Diabetic Kidney Disease
- Satisfaction and efficacy of switching from daily dipeptidyl peptidase-4 inhibitors to weekly trelagliptin in patients with type 2 diabetesโRandomized controlled studyโ
- Prevalence of diabetes mellitus in bullous pemphigoid patients in the absence of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis
- Three ileus cases associated with the use of dipeptidyl peptidaseโ4 inhibitors in diabetic patients
- Dipeptidyl Peptidase-4 InhibitorsโEmerging Player for Vascular Protectionโ
- Response to the dipeptidyl peptidaseโ4 inhibitors in J apanese patients with type 2 diabetes might be associated with a diplotype of two single nucleotideย โฆ
- Dynamics of total volume of pancreatic ฮฑโand ฮฒโcells under the influence sulfonylureas and their combination with dipeptidyl peptidaseโ4 inhibitors
- Association between dipeptidyl peptidase-4 inhibitors and autoimmune disorders: Data mining of the spontaneous reporting system in Japan
- Combination therapy of sodiumโglucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences
- Design, synthesis and evaluation of a series of novel long-acting dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes
- Risk of stent failure in patients with diabetes treated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors: A nationwide observationalย โฆ
- Observational study on dipeptidyl peptidase-4 inhibitors: a real-life analysis on 360 patients from the ASL VCO territory in Italy
- Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes
- Comparing sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on new-onset depression: a propensity score-matched study inย โฆ
- Sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors combination therapy in type 2 diabetes: A systematic review of currentย โฆ
- Comparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies toย โฆ
- Impact of standard-dose dipeptidyl peptidase-4 inhibitors on the incidence of graft-versus-host disease after allogeneic hematopoietic cell transplantation
- Comparative effectiveness of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on noninvasive indices of hepatic steatosis andย โฆ
- Can glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors help in mitigating the risk of atrial fibrillation in patients with diabetes?
- In vitro metabolism and transport of the new dipeptidyl peptidase 4 inhibitors, KR66222 and KR66223
- Impact of dipeptidyl peptidase-4 inhibitors on glycemic control and cardiovascular safety with adherence: an overview
- Efficacy, safety and impact on ฮฒ-cell function of dipeptidyl peptidase-4 inhibitors plus metformin combination therapy in patients with type 2 diabetes and theย โฆ
- Risk of heart failure with dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
- Dipeptidyl peptidase 4 inhibitors
- Network meta-analysis of liraglutide versus dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes in Japanese patients
- Comparative Safety of Dipeptidyl Peptidaseโ4 Inhibitors and Sudden Cardiac Arrest and Ventricular Arrhythmia: PopulationโBased Cohort Studies
- The use of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes & chronic kidney disease
- Reshaping diabetes care: the fundamental role of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists in clinical practice
- Determination of dipeptidyl peptidase-4 inhibitors by spectrophotometric and chromatographic methods
- โฆย with diabetes after peripheral artery disease revascularization treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors
- Shortโterm and longโterm effects of dipeptidyl peptidaseโ4 inhibitors in type 2 diabetes mellitus patients with renal impairment: a metaโanalysis of randomizedย โฆ
- All-cause mortality of insulin plus dipeptidyl peptidase-4 inhibitors in persons with type 2 diabetes
- The roles of dipeptidyl peptidase 4 (DPP4) and DPP4 inhibitors in different lung diseases: new evidence
- New dipeptidyl peptidase 4 inhibitors among adamantane derivatives
- An update in incretin-based therapy: a focus on dipeptidyl peptidase-4 inhibitors
- Comparing adoption of breakthrough and โme-tooโ drugs among Medicare beneficiaries: a case study of dipeptidyl peptidase-4 inhibitors
- Dipeptidyl peptidaseโ4 inhibitors are effective in J apanese type 2 diabetic patients with sustained endogenous insulinโsecreting capacity, a higher body mass indexย โฆ
- Association of the gallbladder or biliary diseases with dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: a meta-analysis of randomizedย โฆ
- Outcomes for inappropriate renal dose adjustment of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: population-based study
- Dipeptidyl peptidase 4 inhibitors linked bullous pemphigoid in patients with type 2 diabetes mellitus: A series of 13 cases
- Benzimidazole-based dual dipeptidyl peptidase-4 and xanthine oxidase inhibitors
- Effect of dipeptidyl peptidase 4 inhibitors used in combination with insulin treatment in patients with type 2 diabetes: a systematic review and meta-analysis
- Dipeptidyl peptidaseโ4 inhibitors and aerobic exercise synergistically protect against liver injury in ovariectomized rats
- Managing hyperglycemia in patients with type 2 diabetes mellitus: rationale for the use of dipeptidyl peptidase-4 inhibitors in combination with other oralย โฆ
- Switching from premixed insulin to basal insulin analogue for type 2 diabetes and role of dipeptidyl peptidase-4 inhibitors
- Do Dipeptidyl Peptidase-4 Inhibitors Increase the Risk of Heart Failure in Patients with Type 2 Diabetes?
- โฆย Synthesis, Biological Evaluation, and Docking Studies of (S)โPhenylalanine Derivatives with a 2โCyanopyrrolidine Moiety as Potent Dipeptidyl Peptidase 4 Inhibitors
- The Potential of some Plant Extracts as Radical Scavengers and Dipeptidyl Peptidase-4 Inhibitors
- The risk of acute pancreatitis after initiation of dipeptidyl peptidase 4 inhibitors: testing a hypothesis of subgroup differences in older US adults
- Cardiovascular effectiveness of glucagon-like peptide 1 receptor agonists versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes: A meta-analysis based onย โฆ
- Bullous Pemphigoid Associated With Dipeptidyl Peptidase-4 Inhibitors: A Case Report and Review of Current Evidence
- Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin: rationale and evidences
- Safety, effectiveness, and cost of dipeptidyl peptidase-4 inhibitors versus intermediate acting insulin for type 2 diabetes: protocol for a systematic review andย โฆ
- Predictors of the efficacy of dipeptidyl peptidase-4 inhibitors in Taiwanese patients with type 2 diabetes mellitus
- Understanding the Role of Dipeptidyl Peptidase-4 Inhibitors in COVID-19: Findings From a Systematic Review
- โฆย prescribing and utilization trends of diabetes medications among patients with renal impairment: emerging role of linagliptin and other dipeptidyl peptidase 4 inhibitors
- Phytochemical content and the potential of Punica granatum peel extracts as radical scavengers and dipeptidyl peptidase-4 inhibitors
- Clinical analysis of pre-existing diabetes mellitus and dipeptidyl peptidase-4 inhibitors in patients with remitting seronegative symmetrical synovitis and pitting edemaย โฆ
- Design, synthesis and anti-diabetic activity of piperazine sulphonamide derivatives as dipeptidyl peptidase-4 inhibitors
- Dipeptidyl peptidase 4 inhibitors and risk of inflammatory bowel disease: real-world evidence in US adults
- โฆย โCoVโ2 vaccineโtriggered conversion from systemic lupus erythematosus (SLE) to bullous SLE and dipeptidyl peptidase 4 inhibitorsโassociated bullous pemphigoid
- โฆย effects of second-line drugs in Japanese patients with type 2 diabetes mellitus: Analysis of claims data for metformin and dipeptidyl peptidase-4 inhibitors as the firstย โฆ
- Structure-based De Novo Design and Docking Studies of 5 (S)-Methyl-LProline Containing Peptidomimetic Compounds as Dipeptidyl Peptidase-4 Inhibitors
- Real-world evaluation of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors for managing type 2 diabetes mellitus: aย โฆ
- Association between dipeptidyl peptidase-4 inhibitors and allergic rhinitis in Asian patients with diabetes
- Dipeptidylโpeptidase (DPP)โ4 inhibitors and glucagonโlike peptide (GLP)โ1 analogues for prevention or delay of type 2 diabetes mellitus and its associatedย โฆ
- Heterogeneous Treatment Effects on Cardiovascular Diseases With Dipeptidyl Peptidaseโ4 Inhibitors Versus Sulfonylureas in Type 2 Diabetes Patients
- Dipeptidyl peptidase-4 inhibitors: sensitivity markers
- Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: evaluation of clinical course and treatment response
- Cardiovascular effects of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists: a review for the general cardiologist
- Association between dipeptidyl peptidaseโ4 inhibitors and increased risk for bullous pemphigoid within 3 months from first use: A 5โyear populationโbased cohortย โฆ
- Dipeptidyl peptidaseโ4 inhibitors and heart failure exacerbation in the veteran population: an observational study
- Potential cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: current evidence and ongoing trials
- Effects of Dipeptidyl Peptidase-4 Inhibitors and Sulfonylureas on Cognitive and Physical Function in Nursing Home Residents
- Dipeptidyl peptidase-4 inhibitors and the ischemic heart: additional benefits beyond glycemic control
- Comprehensive efficacy of ipragliflozin on various conditioned type 2 diabetes compared with dipeptidyl peptidase-4 inhibitors and with both agents, based on a realย โฆ
- Comparison of different case-crossover variants in handling exposure-time trend or persistent-user bias: using dipeptidyl peptidase-4 inhibitors and the risk ofย โฆ
- Comparative effects of sulphonylureas, dipeptidyl peptidaseโ4 inhibitors and sodiumโglucose coโtransporterโ2 inhibitors added to metformin monotherapy: aย โฆ
- Demographic and clinical characteristics of patients with type 2 diabetes mellitus initiating dipeptidyl peptidase 4 inhibitors: a retrospective study of UKย โฆ
- Design, synthesis, and biological evaluation of triazolopiperazine-based ฮฒ-amino amides as potent, orally active dipeptidyl peptidase IV (DPP-4) inhibitors
- Design and synthesis of 3-pyridylacetamide derivatives as dipeptidyl peptidase IV (DPP-4) inhibitors targeting a bidentate interaction with Arg125
- Healthcare costs of the combination of metformin/dipeptidyl peptidase-4 inhibitors compared with metformin/other oral antidiabetes agents in patients with type 2ย โฆ
- โฆย trials of sodium glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor analogues and dipeptidyl peptidase-4 inhibitors to a representativeย โฆ
- Effect of dipeptidyl peptidase-4 inhibitors on glycated hemoglobin levels relies on dietary sodium intake
- New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: A Chinese population-basedย โฆ
- โฆย drugs and drug costs among residents of long-term care facilities under a bundled payment system: Case studies of dipeptidyl peptidase-4 inhibitors and direct oralย โฆ
- Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes
- Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors vs. Dipeptidyl Peptidase-4 Inhibitors in Frail People With Diabetes Who Were Recentlyย โฆ
- Use of dipeptidyl peptidaseโ4 inhibitors and risk of splanchnic vein thrombosis: a Danish nationwide newโuser active comparator cohort study
- Similarity and dissimilarity in antinociceptive effects of dipeptidyl-peptidase 4 inhibitors, Diprotin A and vildagliptin in rat inflammatory pain models following spinalย โฆ
- Synthesis and biological evaluation of azobicyclo [3.3. 0] octane derivatives as dipeptidyl peptidase 4 inhibitors for the treatment of type 2 diabetes
- Cardiovascular and Renal Outcomes With Sodium-Glucose Cotransporter-2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors Combination Therapy: A Meta-Analysis ofย โฆ
- Improvement in mortality and end-stage renal disease in patients with type 2 diabetes after acute kidney injury who are prescribed dipeptidyl peptidase-4 inhibitors
- Synthesis and biological evaluation of bicyclo [3.3. 0] octane derivatives as dipeptidyl peptidase 4 inhibitors for the treatment of type 2 diabetes
- Acquired hemophilia A associated with dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus: a single-center case series in Japan
- Risk of cardiovascular events associated with dipeptidyl peptidase-4 inhibitors in patients with diabetes with and without chronic kidney disease: A nationwideย โฆ
- Vilsmeier reagent initialed sequential one-pot multicomponent synthesis of N, O-disubstituted glycolamides as dipeptidyl peptidase 4 inhibitors
- โฆย with newer agents used to treat type 2 diabetes (T2DM) in the United States: canagliflozin versus dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptideย โฆ
- Comparative risk for cardiovascular diseases of dipeptidyl peptidase-4 inhibitors vs. sulfonylureas in combination with metformin: results of a two-phase study
- Design, synthesis and anti-diabetic activity of novel 1, 2, 3-triazole-5-carboximidamide derivatives as dipeptidyl peptidase-4 inhibitors
- Dipeptidyl Peptidase-4 Inhibitors
- Association between dipeptidyl peptidase-4 inhibitors use and leptin in type 2 diabetes mellitus
- Cardiovascular outcomes of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes on insulin therapy
- Clinical review: Safety and efficacy comparison between sulfonylureas and dipeptidyl peptidase-4 inhibitors as second-line therapies in type 2 diabetes mellitus
- Use of dipeptidyl peptidaseโ4 inhibitors and the risk of arthralgia: Populationโbased cohort and nested caseโcontrol studies
- Risk of myocardial infarction in trials with dipeptidyl peptidase-4 inhibitors: is duration of study a real issue?
- Severe hypoglycemia by combination therapy with dipeptidyl peptidase-4 (DPP-4) inhibitors and sulfonylureas
- Decreased Mortality After Long-Term Treatment With Dipeptidyl Peptidase-4 Inhibitors: A Retrospective Study of US Veterans With Type 2 Diabetes
- Dipeptidyl Peptidase-4 inhibitors and joint pain: a retrospective cohort study of older veterans with type 2 diabetes mellitus
- Optimizing the treatment of newly diagnosed type 2 diabetes mellitus with combination of dipeptidyl peptidase-4 inhibitors and metformin: An expert opinion
- Potential role of dipeptidyl peptidase-4 inhibitors in atrial fibrillation
- Dipeptidyl peptidase-4 inhibitors as a third-line oral antihyperglycaemic agent in patients with type 2 diabetes mellitus: the impact of ethnicity
- Treatment Burden on Once-Weekly Omarigliptin Versus Daily Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes: Randomized Controlled Trialย โฆ
- Comparison of Efficacy of Dipeptidyl Peptidaseโ4 Inhibitors and SodiumโGlucose CoโTransporter 2 Inhibitors Between Japanese and NonโJapanese Patients: A Metaย โฆ
- Design of potent dipeptidyl peptidase IV (DPP-4) inhibitors by employing a strategy to form a salt bridge with Lys554
- Dipeptidyl peptidase-4 inhibitors and protection against stroke: A systematic review and meta-analysis
- โฆย care management of type 2 diabetes: a comparison of the efficacy and safety of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors
- โฆย of ICU Admission and Related Mortality in Patients With Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors: A Territory-Wideย โฆ
- Discovery of potential natural dipeptidyl peptidase-4 inhibitors for type-2 diabetes treatment via structure-based virtual screening
- Efficacy and safety of switching to teneligliptin in patients with type 2 diabetes inadequately controlled with dipeptidyl peptidase-4 inhibitors: 52-week resultsย โฆ
- SVMDLF: A novel Rโbased Web application for prediction of dipeptidyl peptidase 4 inhibitors
- Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with reninโangiotensin system inhibitors in type 2 diabetic patients with albuminuria
- โฆย -induced plasma active glucagon-like peptide-1 levels by co-administration of sodiumโglucose cotransporter inhibitors with dipeptidyl peptidase-4 inhibitors inย โฆ
- Differences in baseline characteristics between type 2 diabetes mellitus patients treated with dipeptidyl peptidase-4 inhibitors in randomized controlled trials and thoseย โฆ
- Efficacy and safety of dipeptidyl peptidase-4 inhibitors: systematic review and meta-analysis
- Metformin combined with dipeptidyl peptidase-4 inhibitors or metformin combined with sulfonylureas in patients with type 2 diabetes: a real world analysis of the Southย โฆ
- Cardiovascular surrogate markers and cardiometabolic therapeutics: a viewpoint learned from clinical trials on dipeptidyl peptidase-4 inhibitors
- Hyperamylasemia is not Associated with Dipeptidyl Peptidase 4 Inhibitors in South Indian Adults with Type 2 Diabetes Mellitus
- Comparing the effect of dipeptidyl-peptidase 4 inhibitors and sulfonylureas on albuminuria in patients with newly diagnosed type 2 diabetes mellitus: A prospectiveย โฆ
- Concordance with prescribing information dosage recommendations for dipeptidyl-peptidase-4 inhibitors among type 2 diabetes mellitus patients with moderate toย โฆ
- Comparative effectiveness of sodium-glucose co-transporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on cardiorenal function and treatment adherence: Aย โฆ
- Correction to:โcardiovascular outcomes comparison of dipeptidyl peptidase-4 inhibitors versus sulfonylurea as add-on therapy for type 2 diabetes mellitus: aย โฆ
- Effect of Add-On Therapy of Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase 4 Inhibitors on Adipokines in Type 2 Diabetes Mellitus
- Economic impact of combining metformin with dipeptidyl peptidase-4 inhibitors in diabetic patients with renal impairment in spanish patients
- Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidenceย โฆ
- Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs
- The dipeptidyl peptidase (DPP)-4 inhibitors for type 2 diabetes mellitus in challenging patient groups
- Differential characteristics of type 2 diabetes in the elderly. Role of dipeptidyl peptidase 4 inhibitors
- Effect of Dipeptidyl Peptidase-4 Inhibitors on Bone Health in Patients with Type 2 Diabetes Mellitus
- SAFETY PROFILE OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS.
- Discovery of 3H-imidazo [4, 5-c] quinolin-4 (5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors
- Dipeptidyl Peptidase 4 Inhibitors and Venous Thromboembolism Risk in Patients with Type 2 Diabetes: A Meta-analysis of Cardiovascular Outcomes Trials
- Inhibitors of dipeptidyl peptidaseโ4 as therapeutic agents for individuals with type 2 diabetes: a 25โyear journey
- Model QSAR Classification Using Conv1D-LSTM of Dipeptidyl Peptidase-4 Inhibitors
- Association between therapy with dipeptidyl peptidase-4 (DPP-4) inhibitors and risk of ileus: a cohort study
- Effect of dipeptidyl peptidase-4 inhibitors inhibitor on cognitive dysfunction in diabetes: A protocol for systematic review and meta analysis
- Efficacy and safety of dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes mellitus patients with moderate to severe renal impairment: a metaย โฆ
- Dipeptidyl peptidase-4 inhibitors and cardiovascular safety
- Impact of Switching from Sulfonylureas to Dipeptidyl Peptidase-4 Inhibitors on Hypoglycemia Burden in the United StatesโA Predictive Modeling Approach
- Comparative risk of musculoskeletal adverse reactions among new users of dipeptidyl peptidase-4 inhibitors: A retrospective cohort study
- โฆย (TECOS) with studyโlevel metaโanalysis of hospitalization for heart failure from cardiovascular outcomes trials with dipeptidyl peptidaseโ4 (DPPโ4) inhibitors
- Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus
- Dipeptidyl peptidase-4 inhibitors
- Insight in the safety profile of antidiabetic agents glucagonโlike peptideโ1 agonists and dipeptidyl peptidaseโ4 inhibitors in daily practice from the patient perspective
- Drug interactions of dipeptidyl peptidase 4 inhibitors involving CYP enzymes and P-gp efflux pump
- Healthcare resource utilization after initiation of sodiumโglucose coโtransporterโ2 inhibitors versus dipeptidyl peptidaseโ4 inhibitors or other glucoseโlowering drugsย โฆ
- Comparison of goat and sheep ฮฒ-lactoglobulin to bovine ฮฒ-lactoglobulin as potential source of dipeptidyl peptidase IV (DPP-4) inhibitors
- Dipeptidyl peptidase-4 inhibitors do not alter GH/IGF-I axis in adult diabetic patients
- Dipeptidyl peptidase 4 inhibitors in routine clinical practice: experiences from a Scottish teaching hospital
- Effect of dipeptidyl peptidase-4 inhibitors on fat metabolism in patients with type 2 diabetes mellitus
- Cardiovascular outcomes comparison of dipeptidyl peptidase-4 inhibitors versus sulfonylurea as add-on therapy for type 2 diabetes mellitus: a meta-analysis
- The role of dipeptidyl peptidase 4 inhibitors in fat metabolism in patients with type 2 diabetes and obesity
- Transitioning from insulin to dipeptidyl-peptidase 4 (DPP-4) inhibitors for type 2 diabetes
- Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors
- Dipeptidyl-peptidase 4 inhibitors
- โฆย between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with kidney outcomes inย โฆ
- Dipeptidyl peptidase-4 inhibitors or sodium glucose co-transporter-2 inhibitors as an add-on to insulin therapy: A comparative review
- In Silico approach for screening of the indonesian medicinal plants database to discover potential dipeptidyl peptidase-4 inhibitors
- Design, synthesis and SAR studies of novel and potent dipeptidyl peptidase 4 inhibitors
- โฆย of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: aย โฆ
- Liver injury with dipeptidyl peptidase-4 (DPP-4) inhibitors (GLIPTINS): signals emerging from the US-FDA Adverse Event Reporting System
- Comment on โOral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case controlย โฆ
- Under-representation of frail older people in meta-analysis of dipeptidyl peptidase-4 inhibitors and hypoglycaemia
- Dipeptidyl peptidase-4 inhibitors: Comparative analysis of members of the group
- Glial cell type-specific changes in spinal dipeptidyl peptidase 4 expression and effects of its inhibitors in inflammatory and neuropatic pain
- โฆย between the use of dipeptidyl peptidase-4 inhibitors (DPP-4i), glucagon-like peptide-1 receptor agonists (GLP-1 RAs), or sodium-glucose cotransporter-2 inhibitors ย โฆ
- Clinical characteristics of bullous pemphigoid in elderly patients with type 2 diabetes mellitus: The association with the use of dipeptidyl peptidase-4 inhibitors
- The many facets of CD26/dipeptidyl peptidase 4 and its inhibitors in disorders of the CNSโa critical overview
- Fracture risk reduction with use of dipeptidyl peptidase-4 inhibitors: is there immortal time bias?
- โฆย Effects of Dipeptidyl Peptidase 4 Inhibitors and Glucagon-Like Peptide 1 Agonist-Administered Concomitant with Sodium-Glucose Cotransporter 2 Inhibitorsย โฆ
- Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors
- Is the popularity of dipeptidyl-peptidase-4 inhibitors justified? Insights from mechanistic studies and clinical trials
- โฆย in the pathogenesis of uterine leiomyoma and the promising anti-fibrotic effects of dipeptidyl peptidase-4 and fibroblast activation protein inhibitors in the treatment ofย โฆ
- Dynamics of switching, adherence, and persistence of dipeptidyl peptidase-4 inhibitors use: A nationwide cohort study
- โฆย hours glucose profile and glycaemic variability evaluated by continuous glucose monitoring in patients with type 2 diabetes receiving dipeptidyl peptidaseโ4 inhibitors
- โฆย Docking Studies of 1โ(ฮณโ1,2,3โTriazol Substituted Prolyl)โ(S)โ3,3โDifluoropyrrolidines as a Novel Series of Potent and Selective Dipeptidyl Peptidaseโ4 Inhibitors
- Odds of acute kidney injury in patients receiving dipeptidyl peptidase 4 inhibitors: a national cohort study within the Department of Veterans Affairs
- Dynamics of total volume of pancreatic ฮฑโand ฮฒโcells under the influence sulfonylureas and their combination with dipeptidyl peptidaseโ4 inhibitors
- Comparison of the effects of Teneligliptin and Sitagliptin, Two Dipeptidyl Peptidase 4 Inhibitors with different half-lives, on glucose fluctuation and glucagon-likeย โฆ
- Fracture risk reduction with use of dipeptidyl peptidase-4 inhibitors: response to Driessen et al.
- Limited Extent of Pleiotropic Effects Mediated by Dipeptidyl Peptidase-4 Inhibitors in Patients With Diabetes Mellitus
- Safety of dipeptidyl peptidase-4 inhibitors in Covid-19: an update
- Evaluation of largeโscale clinical trials on cardiovascular disease risk in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase 4 inhibitors and a newย โฆ
- Cluster analysis in prediction of biological activity and molecular structure relationship of dipeptidyl peptidase-4 inhibitors for the type two diabetes mellitus treatment
- Dipeptidyl peptidase-4 inhibitors do not increase overall adverse events in type 2 diabetes
- Integrated protocol to design potential inhibitors of dipeptidyl peptidase-4 (DPP-4)
- Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors
- Dipeptidyl peptidase-4 inhibitors use in clinical practice
- Drug utilization review of Dipeptidyl Peptidase-4 (DPP-4) inhibitors in Alice Ho Miu Ling Nethersole Hospital (AHNH).
- Efficacy of ฮฑโglucosidase inhibitors combined with dipeptidylโpeptidaseโ4 inhibitor (alogliptin) for glucose fluctuation in patients with type 2 diabetes mellitus byย โฆ
- Bullous Drug Reaction with Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
- Hypoglycemia in the diabetes treatment-risk minimization with dipeptidyl peptidase-4 inhibitors
- A short-term follow-up of glycemic and body weight changes in diabetic patients who replaced dipeptidyl peptidase-4 inhibitors with the sodium-glucose cotransporterย โฆ
- Incretin-based Therapies (Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors) for the Treatment of Type 2 Diabetes
- Use of dipeptidyl peptidase-4 inhibitors in patients with diabetes
- Inclusion of the EXAMINE study in a meta-analysis of the addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia
- Dipeptidyl peptidase-4 inhibitors use and relative risk of ischemic cerebrovascular disease in type 2 diabetic patients in a case-control study
- B-PO05-144 COMPARING SODIUM GLUCOSE COTRANSPORTER 2 INHIBITORS AND DIPEPTIDYL PEPTIDASE-4 INHIBITORS ON NEW-ONSET ATRIALย โฆ
- Association Between Pancreatic Cancer and Dipeptidyl Peptidase-4 Inhibitors Use in a Case-Control Study
- โฆย : traditional hypoglycemic agents (metformin, sulfonylureas, thiazolidinediones) versus glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors
- Author Correction: Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: A meta-analysis of randomized clinical trials
- Design, Synthesis and Biological Evaluation of Novel Imidazolone Derivatives as Dipeptidyl Peptidase 4 Inhibitors
- โฆย and pancreatic cancer in sodium glucose cotransporter 2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP4) inhibitors: a propensity scoreย โฆ
- Dipeptidyl peptidase 4 inhibitors diprotin A and sitagliptin administered on weeks 2-3 of postnatal development modulate monoamine metabolism in the striatum ofย โฆ
- Computationally Guided Design of Dipeptidyl Peptidase-4 Inhibitors
- Dipeptidyl peptidase-4 inhibitors and risk of venous thromboembolism: data mining of FDA adverse event reporting system
- Left Ventricular Size And Function In Patient With Type 2 Diabetes Mellitus Treated With Dipeptidyl Peptidase-4 Inhibitors
- Educating patients with type 2 diabetes on a new class of drug, dipeptidyl peptidase 4 inhibitors
- Canagliflozin (CANA) added on to dipeptidyl peptidase-4 inhibitors (DPP-4i) or glucagon-like peptide-1 (GLP-1) agonists with or without other antihyperglycemicย โฆ
- Research progress of mechanisms through which dipeptidyl peptidase-4 inhibitors regulate glycemia
- Benefits of insulin degludec/liraglutide are maintained even in patients discontinuing sulphonylureas or dipeptidyl peptidaseโ4 inhibitors upon initiation of degludecย โฆ
- Scaffold-hopping from xanthines to tricyclic guanines: A case study of dipeptidyl peptidase 4 (DPP4) inhibitors
- Benzo[4,5]thieno[2,3โd]pyrimidine phthalimide derivative, one of the rare noncompetitive inhibitors of dipeptidyl peptidaseโ4
- Synergistic effect of ฮฑโglucosidase inhibitors and dipeptidyl peptidase 4 inhibitor treatment
- Increased Risk of Hospitalization for Heart Failure with Newly Prescribed Dipeptidyl Peptidase-4 Inhibitors and Pioglitazone Using the Korean Healthย โฆ
- Health economic evaluation of dipeptidyl peptidase-4 inhibitors
- Cardiovascular safety of dipeptidyl peptidase-4 (DPP-4) inhibitors
- A systematic review on the clinical outcomes of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients
- Dipeptidyl peptidase-4 inhibitors in type 2 diabetic elderly patient
- Effect of dipeptidyl peptidase 4 inhibitors on cardiovascular events in type-2 diabetes patients with renal impairment: A systematic review and meta-analysis
- Discovery of 6-(Aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxamides as Potent, Selective Dipeptidyl Peptidase-4 (DPP4) Inhibitors
- โฆย -1-((3aS, 7aS)-octahydro-1H-indol-1-yl)-4-(2, 4, 5-trifluorophenyl) butan-1-one derivatives as potent inhibitors of dipeptidyl peptidase-4: Design, synthesis, biologicalย โฆ
- Retracted: Effect of dipeptidyl peptidaseโ4 inhibitors on the progression of atherosclerosis in patients with type 2 diabetes mellitus: A metaโanalysis of randomisedย โฆ
- Towards evidence-based medicine: large-scale intervention trials with dipeptidyl peptidase-4 inhibitors
- Dipeptidyl peptidase-4 inhibitors and heart failure: friends or foes?
- Pathogenetic background of dipeptidyl peptidase-4 inhibitors application in the management of diabetes mellitus type 2
- Lower risks of sodium glucose cotransporter 2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset non-alcoholic fatty liver diseaseย โฆ
- Risk of heart failure and adverse cardiovascular outcomes with dipeptidyl peptidase-4 inhibitors in type 2 diabetic patients: A meta-analysis of randomized controlledย โฆ
- Effects of Increasing Metformin Dose vs Adding/Switching to Dipeptidyl Peptidase-4 Inhibitors on Glycemic Control in Patients with Type 2 Diabetes
- Sodium Glucose Cotransporter-2 Inhibitors as an Add-on Therapy to Metformin Plus Dipeptidyl Peptidase-4 Inhibitor in Patients with Type 2 Diabetes
- Combination therapy with dipeptidyl peptidase-4 and P2X7 purinoceptor inhibitors gives rise to antiepileptic effects in rats
- CD26/Dipeptidyl Peptidase-4 Inhibitors as Prophylaxis of Chronic Lung Allograft Dysfunction after Lung Transplantation, a Clinicopathological Evaluation
- Dipeptidyl Peptidase-4 Inhibitors and Beta Cell Mass in Japanese Adults with Type 2 Diabetes
- The roles of dipeptidyl peptidase-4 and its inhibitors in the regulation of airway epithelial-mesenchymal transition
- 1386-P: Dipeptidyl Peptidase-4 Inhibitors and the Risk of Skin Cancer among Patients with Type 2 DiabetesโPopulation-Based Cohort Study
- Progress in dipeptidyl peptidase-4 and its inhibitors
- Further possible mechanisms of dipeptidyl peptidase-4 inhibitors to decrease blood glucose in subjects with type 2 diabetes
- Candidate Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes
- CLINICAL ASPECTS FOR USE OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS IN COMBINATION WITH METFORMIN: BENEFITS FOR DIFFERENT GROUPS OFย โฆ
- Contemporary trends in prescription of dipeptidyl Peptidase-4 inhibitors in the context of US food and drug administration warnings of heart failure risk
- Combined Ligand-Based and Structure-Based Virtual Screening Approach for Identification of New Dipeptidyl Peptidase 4 Inhibitors
- The Old and the new in the Treatment of Type 2 Diabetes: Focus on the combination Therapy with Dipeptidyl peptidase-4 Inhibitors and Metformin
- EPH54 Cancer Associations with Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)
- Effect of Dipeptidyl peptidase-4 inhibitors on the progression of atherosclerosis in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
- Sitagliptin and vildagliptin use evaluation among dipeptidyl peptidase 4 inhibitors in adult Koreans with type 2 diabetes mellitus
- ฮullous Pemphigoid Associated with Dipeptidyl Peptidase 4 Inhibitors for the Treatment of Type 2 Diabetes: A Multicenter Study in Istanbul
- Latent class analysis of patients’ background factors affecting the risk of specific adverse drug reactions to dipeptidyl peptidase 4 inhibitors.
- Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2015; 39: 342-7)
- Comment on โOral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-controlย โฆ
- Response: Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2015; 39: 342-7)
- Dipeptidyl peptidase-4 inhibitors and mortality risks in patients with prostate cancer receiving androgen deprivation therapy: a population-based cohort study
- Dipeptidyl Peptidase-4 (DPP4) Inhibitors
- Co-medications and dipeptidyl peptidase-4 inhibitors associated bullous pemphigoid,
- In type 2 diabetes, dipeptidyl peptidase-4 inhibitors do not increase pancreatitis
- Cost and utilization outcomes after exclusion of dipeptidyl peptidase-4 inhibitors and other diabetes drug category changes in a self-funded, state employee managedย โฆ
- Erroneous Event Count in a Meta-Analysis (Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Mellitus)
- Meta-analysis of HbA1c-lowering efficacy of dipeptidyl peptidase-4 inhibitors in combination with insulin in T2DM patients
- FC 125: Comparative Effectiveness of Dipeptidyl Peptidase-4 Inhibitors versus Sulfonylureas in Addition to Metformin: A Population-Based Cohort Study of Patientsย โฆ
- Comment on: Monami et al. Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures: A Meta-analysis of Randomized Clinical Trials. Diabetes Care 2011; 34: 2474โ2476
- PDB22 potential budget impact of linagliptin in France estimated from current pattern of dipeptidyl peptidase 4 inhibitors prescriptions
- Repurposing of Dipeptidyl Peptidase-4 Inhibitors
- SARS-CoV-2 and diabetes: A potential therapeutic effect of dipeptidyl peptidase 4 inhibitors in diabetic patients diagnosed with COVID-19
- Identification of Dipeptidyl peptidase-4 (DPP-4) inhibitors as Potential Antidiabetic agents using Molecular docking study
- Comparisons of Efficacy Between Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase 4 Inhibitors Add-on to Metformin Therapy in Type 2ย โฆ
- QSAR rationales for the dipeptidyl peptidase-4 (DPP-4) inhibitors: The imidazolopyrimidine amides
- Discovery of 3H-imidazo [4, 5-c] quinolin-4 (5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors: use of a carboxylate prodrug to improveย โฆ
- DIPEPTIDYL PEPTIDASE-4 INHIBITORS-NEW POTENTIALS FOR TREATMENT OF TYPE 2 DIABETES MELLITUS: EXPERIENCE OF USE OF GALVUS MET INย โฆ
- The efficacy and safety of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 agonists in pediatric patients with type 2 diabetes: a systematic review
- Adherence to Oral Antihyperglycemic Agents (Dipeptidyl Peptidase-4 Inhibitors and Biguanides) and Its Associated Factors in Patients with Type 2 Diabetes
- Factors associated with the discontinuation of dipeptidyl peptidase-4 inhibitors (DPP-4is) after initiation of insulin
- Incretin-based Therapies: Dipeptidyl Peptidase-4 Inhibitors
- โฆย as dipeptidyl peptidase IV inhibitors: profile of clinical candidate (2R, 3S, 5R)-2-(2, 5-difluorophenyl)-5-[2-(methylsulfonyl)-2, 6-dihydropyrrolo [3, 4-c] pyrazol-5 (4H)-yl]ย โฆ
- 4-arylcyclohexylalanine analogs as potent, selective, and orally active inhibitors of dipeptidyl peptidase IV
- Dipeptidyl Peptidase-4 Inhibitors Reduced Long-term Cardiovascular Risk in Japanese Diabetic Patients After Percutaneous Coronary Intervention via Insulin-likeย โฆ
- Pooled patient level data are better suited than study level data to investigate the link between dipeptidyl peptidase-4 inhibitors and the risk of heart failure in type 2ย โฆ
- A comparative study of the in vitro antioxidant activity of dipeptidyl peptidase-4 inhibitors
- Evaluation of Dipeptidyl Peptidase-4 Inhibitors versus Thiazolidinediones or Insulin in Patients with Type 2 Diabetes Uncontrolled with Metformin and aย โฆ
- The Beneficial Effects of Switching from Dipeptidyl Peptidase-4 Inhibitors to Dulaglutide on Plasma Glucose and Hemoglobin A1c Levels: A Case Report of Fourย โฆ
- Impact of standard-dose dipeptidyl peptidase-4 inhibitors on the incidence of graft-versus-host disease among diabetes mellitus patients undergoing allogeneicย โฆ
- Optimization of 1, 4-diazepan-2-one containing dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes
- Role of Incretin, Incretin Analogues and Dipeptidyl Peptidase 4 Inhibitors in the Pathogenesis and Treatment of Diabetes Mellitus
- Role of incretin, incretin analogues and dipeptidyl peptidase 4 inhibitors in the pathogenesis and treatment of diabetes mellitus
- Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: the importance of the pharmacotherapeutic history
- 865-P: Hypoglycemia Risk Is Similar with Dipeptidyl Peptidase-4 Inhibitors (DPP-4i) Monotherapy vs. Metformin Monotherapy
- Research Progress in Dipeptidyl Peptidase-4 Inhibitors
- Effectiveness in clinical practice versus efficacy of dipeptidyl peptidase-4 inhibitors in clinical trials for type 2 diabetes: protocol for systematic review
- 122 Comparing dipeptidyl peptidase-4 inhibitors and sodium-glucose cotransporter-2 inhibitors on new-onset heart failure and myocardial infarction
- โฆย utilization comparison of patients with type 2 diabetes on sodiumโglucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: evidence from 2015 toย โฆ
- โฆย Comparison to Evaluate the Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors (DPP4I) and Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2I) Added toย โฆ
- Design and elaboration of a tractable tricyclic scaffold to synthesize druglike inhibitors of dipeptidyl peptidase-4 (DPP-4), antagonists of the CโC Chemokine Receptorย โฆ
- Nonglycemic effects of dipeptidyl peptidase-4 inhibitors
- โฆย Diabetes: Better Renal Outcomes in Patients with Type 2 Diabetes Taking Sodium-Glucose Cotransporter 2 Inhibitors versus Dipeptidyl Peptidase-4 Inhibitors
- Cardiovascular outcomes during treatment with dipeptidyl peptidase-4 inhibitors depending on renal function and combination with metformin: a systematic review
- Association Between Dipeptidyl Peptidase-4 Inhibitors and Diabetic Retinopathy in Korean Patients With Type 2 Diabetes Mellitus: Nationwide Population-Basedย โฆ
- Identification of Dipeptidyl Peptidase-4 and ฮฑ-Amylase Inhibitors from Melicope glabra (Blume) TG Hartley (Rutaceae) Using Liquid Chromatography Tandem Massย โฆ
- โฆย transโdecalin spiroโฮณโlactone, from pharaoh cuttlefish Sepia pharaonis: Twin inhibitors of inflammatory 5โlipoxygenase and serine protease dipeptidyl peptidaseโ4
- Evaluation of Hypoglycaemic Effects of Dipeptidyl Peptidaseโ4 Inhibitors and Biguanide on Type-2 Diabetic subjects: A six months trial
- Impact of Dipeptidyl Peptidase-4 Inhibitors on The Risk of Cardiovacular-Related Hsopitalizations
- Therapeutic Role of Dipeptidyl Peptidase-4 Inhibitors in COVID-19
- โฆย Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review
- # 6153 SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS VERSUS DIPEPTIDYL PEPTIDASE 4 INHIBITORS AS STABILIZERS OF HIF PATHWAY IN DIABETICย โฆ
- Effect of dipeptidyl peptidase-4 inhibitors and sodium-glucose cotransporter-2 inhibitors on retinal complications in type 2 diabetic patients
- Dipeptidyl Peptidase 4 Inhibitors for Type 2 Diabetes and Relationships to Diabetic Macular Edema
- Comparison of Effect of Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors with Dipeptidyl Peptidase-4 (DPP-4) Inhibitors on HBA1c Level in Type 2 Diabetes inย โฆ
- Dipeptidyl peptidase 4 inhibitors and bullous pemphigoidโ more evidence of a link: a report of three cases
- In silico discovery of potential inhibitors against Dipeptidyl Peptidase-4: A major biological target of type-2 diabetes mellitus
- Combined effect of sodiumโglucose cotransporter 2 and dipeptidyl peptidaseโ4 inhibitors for diabetic kidney disease
- The effect of dipeptidyl peptidase-4 inhibitors or curcumin on diet induced metabolic syndrome with cardiac dysfunction in rats
- 1138-P: Dipeptidyl Peptidase-4 Inhibitors Attenuate Thyroid-Stimulating Hormone Levels
- Assessing the association between dipeptidyl peptidase-4 inhibitors use and celiac disease through drug adverse event reporting
- Role of cardiovascular protection played by dipeptidyl peptidase 4 inhibitors
- EFFICACY OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS THERAPY IN DIFFERENT POPULATIONS
- Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome
- โฆย of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes showing inadequate response to thrice-a-day treatment with ฮฑ-glucosidase inhibitors
- Association of sulphonylureas and dipeptidyl peptidase-4 inhibitors with cardiovascular disease: population-based cohort study
- Dipeptidyl peptidase 4 inhibitors reduce costs in T2DM management
- 4-Aminophenylalanine and 4-aminocyclohexylalanine derivatives as potent, selective, and orally bioavailable inhibitors of dipeptidyl peptidase IV
- The mechanism of the action of dipeptidyl peptidase-4 inhibitors and its use in type 2 diabetes
- Association of sodiumโglucose cotransporterโ2 inhibitors versus dipeptidyl peptidaseโ4 inhibitors with time to dementia: a populationโbased cohort study
- Effects of Increasing Metformin Dose vs Adding/Switching to Dipeptidyl Peptidase-4 Inhibitors on Glycemic Control in Patients with Type 2 Diabetes
- Are dipeptidyl peptidase-4 inhibitors effective and safe in long term when added to ongoing therapies of diabetics? a real-life study in tertiary referral center
- In silico study of four alkaloids as dipeptidyl peptidase-4 (DPP4) inhibitors to generate anti-diabetics effect
- โฆย -P: A Population-Based Assessment of the Risk of Severe Hypoglycemia with Concomitant Use of Sulfonylureas and Peptidomimetic Dipeptidyl Peptidase-4 Inhibitors
- Investigation of cardiotoxicity by dipeptidyl-peptidase-4 inhibitors in a human cardiomyocyte cell line as well as in samples from chronic heart failure patients
- Study the effect of Dipeptidyl Peptidase 4 Inhibitors as an Antidiabetic in Type 2 Diabetes Mellitus (T2DM)
- Evaluation of Efficacy and Safety for Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients
- The Effect of Dipeptidyl Peptidase-4 Inhibitors on Carotid Intima-media Thickness in Patients With Type 2 Diabetes Mellitus: a Meta-analysis
- Diabetes and cardiovascular risk: are dipeptidyl peptidase-4 inhibitors beneficial?
- โฆย of 3-aminomethyl-1, 2-dihydro-4-phenyl-1-isoquinolones: a new class of potent, selective, and orally active non-peptide dipeptidyl peptidase IV inhibitors that form aย โฆ
- Patient-Reported Outcomes of Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review
- Electronic medical records-based comparison of glycemic control efficacy between sulfonylureas and dipeptidyl peptidase-4 inhibitors added on to metforminย โฆ
- Sulfonylureas or dipeptidyl peptidase (DPP-4) inhibitors in the management of type 2 diabetes: debate is not yet closed
- Response to Letter Regarding Article,โCardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylurea as Add-on Therapy for Type 2ย โฆ
- Effect of dipeptidyl peptidase-4 inhibitors on cardiovascular outcome
- Meta-analysis of cardiovascular outcome trials assessing the cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetesย โฆ
- Dipeptidyl Peptidase-4 Inhibitors Do Not Exacerbate Heart Failure
- Synthesis and SAR Study of Chloro-Retrochalcone Derivatives as Dipeptidyl Peptidase 4 Inhibitors with Anti-Inflammatory Effects
- BENEFICIAL EFFECTS OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS ON VASCULAR DYSFUNCTION
- Impact of antidiabetic treatment with dipeptidyl peptidase-4 inhibitors on the risk of cardiac arrhythmias among patients with type 2 diabetes mellitus
- The Safety Profile Comparison Between Dipeptidyl Peptidase-4 Inhibitors and Sulfonylureas in Diabetic Patients: A Systematic Review and Meta-Analysis
- Dipeptidyl Peptidase-4 Inhibitors Significantly Reduce the Incidence of First Cardiovascular Events in Diabetic Patients
- Dipeptidyl-peptidase-4 Inhibitors for Treatment of Type 2 Diabetes
- PDB10 A Meta-Analysis of Efficacy and Safety of Dipeptidyl Peptidase-4 [Dpp-4] Inhibitors in Type 2 Diabetes
- Emerging GLP-1 analogues and dipeptidyl peptidase 4 (DPP-4) inhibitors
- Cardiovascular Outcome Trials with Dipeptidyl Peptidase-4 Inhibitors
- A DIFFERENTIATED APPROACH TO PRESCRIBING DIPEPTIDYL PEPTIDASE-4 INHIBITORS
- A Prospective Observational Study of Comparison, Safety, and Efficacy of Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus in A Tertiaryย โฆ
- Genetic predictors of the pharmacological effects of dipeptidyl peptidase-4 inhibitors and sulfonylureas in patients with type 2 diabetes mellitus
- Effect of dipeptidyl peptidase-4 inhibitors linagliptin on the expression of serum pigment epithelium-derived factor in type 2 diabetes patients
- Prescribing pattern of dipeptidyl peptidase 4 inhibitors and level of HBA1C target achievements among outpatients with type 2 diabetes mellitus in a Malaysianย โฆ
- 2209-PUB: Factors Associated with Switching from Sulfonylureas (SUs) to Dipeptidyl Peptidase-4 Inhibitors (DPP-4i) among Individuals with Type 2 Diabetes in theย โฆ
- Diabetes Mellitus: Dipeptidyl Peptidase 4 Inhibitors and Cardiovascular Outcomes
- Real-world adherence, persistence, and in-class switching during use of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis involving 594,138ย โฆ
- Dipeptidyl Peptidase 4 Inhibitors and the Risk of Heart Failure 126
- Risk of Pancreatic Cancer and Use of Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes: A Propensity Score-Matching Analysis
- Lower COVID-19 Mortality in Patients with Type 2 Diabetes Mellitus Taking Dipeptidyl Peptidase-4 Inhibitors: Results from a Turkish Nationwide Study
- Effect of Dipeptidyl Peptidase-4 Inhibitors on Plasma Adiponectin: A Systematic Review and Meta-Analysis of
- Cardiovascular Preventing Effects of Dipeptidyl Peptidase-4 Inhibitors: Beyond Glucagon-Like Peptide-1
- Dipeptidyl peptidase 4 inhibitors for the treatment of type 2 diabetes mellitus
- Correction: The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
- MO38-5 Dipeptidyl peptidase-4 inhibitors and risk of gall bladder cancer in type 2 diabetes patients: A meta-analytic synthesis
- Changes in prescribing of sodium-glucose co-transporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors in Singapore
- Emerging Role of Dipeptidyl Peptidase-4 Inhibitors in the Management of Type 2 Diabetes Mellitus
- Efficacy of switching from dipeptidyl peptidase-4 inhibitors to dulaglutide in patients with type 2 diabetes
- Comparison of cardiovascular and renal outcomes between sodium glucose coโtransporterโ2 and dipeptidyl peptidaseโ4 inhibitors among type 2 diabetes patients: aย โฆ
- Dipeptidyl peptidase-4 inhibitors Mitigates Glycemic Variability in Metformin based Multiple Daily injected Type 2 Diabetes, a Prospective Randomized Controlled Trial
- PDB101 PATTERNS OF ADHERENCE, PERSISTENCE, AND SWITCHING AMONG AUSTRALIANS PRESCRIBED DIPEPTIDYL PEPTIDASE-4 INHIBITORS
- O145 Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: Meta-analysis of randomized clinical trials
- Dipeptidyl Peptidase-4 Inhibitors, a New Option for the Management of Type 2 Diabetes Mellitus
- Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients: A Meta-Analysis of 95 Trials
- Risk of Dipeptidyl-Peptidase-4 (Dpp-4) Inhibitors On Site-Specific Cancer: A Systematic Review And Meta-Analysis
- Comparing the Risk of Heart Failure Among Different Dipeptidyl Peptidase 4 Inhibitors
- Effect of Add-On Therapy of Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase 4 Inhibitors on Adipokines in Type 2 Diabetes Mellitus
- Dipeptidyl peptidase-4 inhibitors induced inflammatory bowel disease in type 2 diabetes patients: A case control study in a South-Indian tertiary care hospital
- Research progress of dipeptidyl peptidase 4 inhibitors on healing of chronic diabetic foot ulcers
- Development of analytical methods for quantitative estimation of Dipeptidyl Peptidase-4 inhibitors in bulk and Pharmaceutical formulations
- DIPEPTIDYL PEPTIDASE-4 INHIBITORS AND CARDIOVASCULAR OUTCOMES: META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS WITH 55,141ย โฆ
- EFFICACY OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS FOR CARDIAC FUNCTION IN DIABETIC PATIENTS WITH ISCHEMIC HEART DISEASE
- Evolution of the Market for oral Antidiabetic agents In Canada after Introduction of Dipeptidyl Peptidase-4 Inhibitors
- POTENTIALS FOR USE OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS IN TYPE 2 DIABETES MELLITUS: INITIATION AND CONTINUATION OF THERAPY
- Dipeptidyl peptidase-4 inhibitors and bone fractures: A Meta-analysis of randomized clinical trials
- Trust and VERIFY: the role of combined treatment with metformin and dipeptidyl peptidase-4 inhibitors in new-onset diabetes type 2
- โฆย ASSESSMENT OF SWITCHING FROM DIPEPTIDYL PEPTIDASE-4 INHIBITORS TO SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS OR GLUCAGON-LIKEย โฆ
- Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes patients: a propensity scoreย โฆ
- Real world evidence on the disparities in prescribing of dipeptidyl peptidase-4 inhibitors in UK primary care
- COMPARATIVE SAFETY OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS AND SULFONYLUREAS IN OLDER ADULTS ACROSS LEVELS OF FRAILTY
- Factors associated with physician prescribing behavior of dipeptidyl peptidase-4 inhibitors for type 2 diabetes in the US outpatient population
- Costs for Diabetic Patients Receiving Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in US Medicare and Commercial Insurance Plans
- High concentrations of dipeptidyl peptidase-4 inhibitors suppressed lipopolysaccharide-induced inflammatory cytokine expression in U937 cells
- Risk of Cardiovascular Events and Medical Cost of Dapagliflozin and Dipeptidyl Peptidase-4 Inhibitors
- PDB15-CARDIOVASCULAR SAFETY OF EMPAGLIFLOZIN VERSUS DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS: SYSTEMATIC LITERATURE REVIEW ANDย โฆ
- Comparative effects of sodium glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP4) inhibitors on new-onset atrial fibrillation and strokeย โฆ
- Cardiovascular safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus
- Treatment with dipeptidyl peptidase-4 inhibitors may induce bullous pemphigoid in patients with type 2 diabetes
- DIPEPTIDYL PEPTIDASE-4 INHIBITORS WERE ASSOCIATED WITH THE REDUCED LONG-TERM RISK OF ADVERSE CARDIOVASCULAR EVENTS IN JAPANESEย โฆ
- Identification of dipeptidyl peptidase-4 inhibitors among boioactive peptides derived from whey proteins
- Beneficial Impact of Dipeptidyl-peptidase-4 inhibitors on Mortality of Patients With Hospitalized Heart Failure Patients With Diabetes Mellitus
- The Effect Of Dipeptidyl-Peptidase-4 Inhibitors On Asthma Control: An Administrative Database Study To Evaluate A Potential Pathophysiological Relationship
- DIPEPTIDYL PEPTIDASE-4 INHIBITORS IN COMBINATION WITH METFORMIN: EXPERIENCE OF USE OF GALVUS MET IN REAL-LIFE CLINICAL PRACTICE INย โฆ
- Dipeptidyl Peptidase-4 Inhibitors and Joint Pain: A Retrospective Cohort Study of Older Veterans with Type 2 Diabetes Mellitus
- Systematic Review of Economic Evaluations of Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus
- 3D QSAR and Pharmacophore Identification of Heteroarylpiperazine-Substituted l-Prolylthiazolidines as Dipeptidyl Peptidase-4 Inhibitors
- P0633 EFFECT OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS ON CISPLATIN-INDUCED ACUTE NEPHROTOXICITY IN CANCER PATIENTS WITH DIABETESย โฆ
- 1258-P: Physician Survey on Discontinuing Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) following Insulin Initiation in Patients with Type 2 Diabetes (T2D) in the US
- Emerging Safety Issues of Dipeptidyl Peptidase-4 Inhibitors and Sodium Glucose Cotransporter 2 Inhibitors: How to Interpret and Apply in Clinical Practice
- Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy.
- Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2015; 39: 342-7)
- Cardiovascular Outcome Trials of Incretin Therapy (Dipeptidyl Peptidase-4 Inhibitors/Glucagon-Like Peptide-1 Receptor Agonist)
- Synthesis and structureโactivity relationships of potent 4-fluoro-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors
- EFFICACY AND TOLERABILITY OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS IN PATIENTS WITH DIABETES MELLITUS AND RENAL IMPAIRMENT: A SYSTEMATICย โฆ
- Response: Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients (Diabetesย โฆ
- Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients (Diabetes Metab Jย โฆ
- Two-Year Assessment of the Therapeutic Efficacy of Dipeptidyl Peptidase-4 Inhibitors or Sulfonylureas in Japanese Drug-Naive Patients With Type 2 Diabetes (JDDMย โฆ
- Differences in Cardiovascular and Renal Outcomes Between Sodium Glucose Co-Transporter-2 and Dipeptidyl Peptidase-4 Inhibitors Among Type 2 Diabetesย โฆ
- Do sodium glucose transporter-2 inhibitors reduce HbgA1c levels more than dipeptidyl peptidase-4 inhibitors?
- Metformin in Combination With Dipeptidyl Peptidase-4 Inhibitors or Sulfonylureas in The Treatment of Type 2 Diabetes: Clinical And Economic Impact
- Impact of Systemic Dipeptidyl Peptidase-4 (DPP-4) Inhibitors on Treatment Outcomes for Diabetic Macular Edema (DME) in the VISTA and VIVID trials
- Clinical Outcomes and Health Care Costs Evaluation of Sulfonamides and Thiazolidinediones Compared with Dipeptidyl Peptidase 4 Inhibitors for the Treatment ofย โฆ
- Dipeptidyl Peptidase-4 Inhibitors May Reduce the Risk of Major Adverse Cardiovascular Events and All-cause Mortality In Patients With Type 2 Diabetes: Metaย โฆ
- 151-LB: High Risk of Krebs Von Den Lungen-6 (kL-6) Elevation when Dipeptidyl Peptidase-4 Inhibitors and Amiodarone Are Prescribed Simultaneously
- Synthesis and structure: activity relationships of potent 1-(2-substituted-aminoacetyl)-4-fluoro-2-cyanopyrrolidine dipeptidyl peptidase 4 inhibitors
- Outcomes Associated With the Adjunctive Use of Dipeptidyl Peptidase-4 Inhibitors With Insulin Versus Other Antihyperglycemic Medications in Patients Withย โฆ
- Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: a systematic review and meta-analysis of randomized and observational studies
- Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Basedย โฆ
- Comparison of glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mettilus
- Response: Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Realย โฆ
- 4-Amino cyclohexylglycine analogues as potent dipeptidyl peptidase IV inhibitors
- Differential Effects of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors on Insulin Resistance and b-Cell Function in Type 2 Diabetes Mellitus: Aย โฆ
- โฆย trials of sodium glucose co-transporter 2 inhibitors, glucagon-like peptide-1 receptor analogues and dipeptidyl peptidase-4 inhibitors to a representative routineย โฆ
- โฆย HbA1C Reduction Associated With Initial Versus Sequential Combination Therapy With Pioglitazone (PIO) and Dipeptidyl Peptidase-4 Inhibitors (DPP4i) in Patientsย โฆ
- Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohortย โฆ
- TREATMENT OPTIMIZATION WITH SODIUM/GLUCOSE COTRANSPORTER-2 INHIBITORS, DIPEPTIDYL PEPTIDASE-4 INHIBITORS OR GLYCAGONE LIKEย โฆ
- Combined use of dipeptidyl peptidase-4 inhibitors and metformin reduces blood sugar level and improves pancreatic islet ฮฒ cell function in the treatment of typeย โฆ
- Cardiovascular Effectiveness of Empagliflozin Compared to Glucagon Like Peptide-1 Receptor Agonists and to Dipeptidyl Peptidase-4 Inhibitors in Older Patientsย โฆ
- Cost-Utility Analysis of Glucagon-Like Peptide-1 Agonists Compared with Dipeptidyl Peptidase-4 Inhibitors or Neutral Protamine Hagedorn Basal Insulin as Add-On toย โฆ
- Glucagon-Like Peptide-1 Receptor Agonists, Dipeptidyl Peptidase-4 Inhibitors, and Risk of Acute Pancreatitis: A Meta-analysis of Randomized Clinical Trial andย โฆ
- Reply to:โComment on ‘Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide caseย โฆ
- โฆย COTRANSPORTER-2 (SGLT2) INHIBITORS, GLUCAGON-LIKE PEPTIDE 1 (GLP-1) RECEPTOR AGONISTS, DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS: Aย โฆ
- A Real-World Disproportionality Analysis of Atrial Fibrillation Adverse Events for Glucagon Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
- New trends in the treatment of type 2 Diabetes Mellitus: a review of Thiazolidinediones, GLP-1 agonists, Dipeptidyl Peptidase-4 inhibitors, and SGLT-2 inhibitors
- Novel series of 3-amino-N-(4-aryl-1, 1-dioxothian-4-yl) butanamides as potent and selective dipeptidyl peptidase IV inhibitors
- Soluble Dipeptidyl Peptidase-4 Induces Endothelial Dysfunction by the Release of Vasoconstrictor Prostanoids: Protective Effect of Dipeptidyl Peptidase Inhibitors
- Angioprotektivnoe properties lowering drugs from the group of inhibitors of dipeptidyl peptidase-4
- FC 2-6: Increased risk of bullous pemphigoid in patients with diabetes mellitus receiving dipeptidyl peptidase-4 inhibitors: A nationwide populationbased study
- Reply to the letter by P. Guillausseau Regarding โSulfonylureas or Dipeptidyl Peptidase (DPP-4) Inhibitors in the Management of Type 2 Diabetes: Debate Is Not Yetย โฆ
- Dipeptidyl peptidase 4 inhibitors and Glucagon-like peptide-1 receptor agonist mitigate inflammation and fibrosis in models of Non-alcoholic steatohepatitis and biliaryย โฆ
- Are Dipeptidyl Peptidase (DPP)-4 Inhibitors Safe in Patients with Heart Failure?
- Influence of inhibitors of dipeptidyl peptidase-4 (DPP-4) on naloxone-induced morphine withdrawal signs in rats
- โฆย Etanercept; Fondaparinux Hepatotoxicity in a 6-Year-Old Child; Bullous Pemphigoid Induced by Dipeptidyl Peptidase-4 Inhibitors; Severe Neuroleptic Malignantย โฆ
- UNEXPECTED ADVERSE REACTIONS OF THE DRUGS OF THE GROUP OF INHIBITORS OF DIPEPTIDYL PEPTIDASE-4
- โฆย of hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus on glucagon-like peptide-1 receptor agonists or dipeptidyl peptidase-4 inhibitors as add-onย โฆ
- Sodium-glucose Cotransporter-2 Inhibitors as Modulator of Dipeptidyl Peptidase-4 in Diabetes
- Health Expenditure Comparison of Diabetic Patients on Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Vs Dipeptidyl Peptidase-4 (DPP4) Inhibitors
- โฆย 24-hour glucose profile and glycemic variability evaluated by continuous glucose monitoring in patients with type 2 diabetes receiving dipeptidyl peptidase-4 inhibitorsย โฆ
- Diabetes mellitus therapy adherence and therapy characterization in Northeast Portugal: classical vs dipeptidyl peptidase iv (dpp-4) inhibitors
- Screening for Dipeptidyl Peptidase IV (DPP-4) inhibitors from Thai herbal medicines use in traditional anti-diabetes recipe
- Substituted pyrrolidine-2, 4-dicarboxylic acid amides as potent dipeptidyl peptidase IV inhibitors
- Targeting Dipeptidyl peptidase-4 (DPP4) by peptide inhibitors for the management of Type-2 diabetes and its complications.
- dipeptidyl-peptidase IV (DPP-4) inhibitors at the highest maintenance doses evaluated in this meta-analysis and systematic review of the efficacy of incretin-basedย โฆ
- OUTCOME EVALUATION OF DIPEPTIDYL PEPTIDASE 4 (DPP4) INHIBITORS AND ITS COMBINATION ON GLYCEMIC CONTROL OF TYPE 2
- Synthesis and structureโactivity relationships of potent 3-or 4-substituted-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors
- Synthesis and StructureโActivity Relationships of Potent 1-(2-Substituted-aminoacetyl)-4-fluoro-2-cyanopyrrolidine Dipeptidyl Peptidase IV Inhibitors
- Outcome evaluation of dipeptidyl peptidase 4 (DPP4) inhibitors and its combination on glycemic control of type 2 diabetes mellitus patients at Putrajaya Hospital
- Effect of Dipeptidyl Peptidase Inhibitors-4 and Sulfonylurea on Serum Adiponectin Levels in Patients with Newly Diagnosed Type 2 Diabetes Mellitus.
- In Silico Design, Synthesis and In Vitro Evaluation of Quinazolinone Derivatives as Dipeptidyl Peptidase-4 (DPP-IV) Inhibitors
- Synthesis, Docking and In-Vitro Studies of Quinazoline Derivatives as Dipeptidyl Peptidase-4 and ฮ-Amylase Inhibitors for Treating Diabetes
- A Decision-Focused Network Meta-Analysis (NMA) of Dipeptidyl Peptidase-4 (DPP4) Inhibitors Used In Combination With Metformin And A Sulfonylurea For Theย โฆ
- Comparison of efficacies of a dipeptidyl peptidase 4 inhibitor and ฮฑ-glucosidase inhibitors in oral carbohydrate and meal tolerance tests and the effects of theirย โฆ
- โฆย and biological evaluation of 4-fluoropyrrolidine-2-carbonitrile and octahydrocyclopenta [b] pyrrole-2-carbonitrile derivatives as dipeptidyl peptidase IV inhibitors
- 1, 3-disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo [a] quinolizine dipeptidyl peptidase IV inhibitors
- ฮณ-Amino-Substituted Analogues of 1-[(S)-2,4-Diaminobutanoyl]piperidine as Highly Potent and Selective Dipeptidyl Peptidase II Inhibitors
- Structural Requirements for some 3-amino-Nsubstituted-4-(substituted phenyl) Butanamides as Dipeptidyl Peptidase-IV Inhibitors Using 3D-QSAR and Molecularย โฆ
- Substituted piperidinyl glycinyl 2-cyano-4, 5-methano pyrrolidines as potent and stable dipeptidyl peptidase IV inhibitors
- โDipeptidyl Peptidase Inhibitorsโ Patent Act, Secs. 21 (2) No. 1, 34 (4)
- (3R, 4S)-4-(2, 4, 5-Trifluorophenyl)-pyrrolidin-3-ylamine inhibitors of dipeptidyl peptidase IV: Synthesis, in vitro, in vivo, and X-ray crystallographic characterization
- โฆย tetrahydropyran analogs as dipeptidyl peptidase IV inhibitors: Profile of clinical candidate (2R, 3S, 5R)-2-(2, 5-difluorophenyl)-5-(4, 6-dihydropyrrolo [3, 4-c] pyrazol-5ย โฆ
- Design and synthesis of 4โ(2, 4, 5โtrifluorophenyl) butaneโ1, 3โdiamines as dipeptidyl peptidase IV inhibitors
